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ITALIAN ABSTRACT 
 
 
 
 
 
 
 
 
 
 
 
Il presente lavoro di tesi è frutto dell’attività di stage svolta presso il dipartimento R&D 
di Lima Corporate s.p.a. di Villanova di San Daniele del Friuli (UD). Il programma di tesi si 
inserisce all’interno di un progetto di ricerca e sviluppo finalizzato alla realizzazione di un 
dispositivo per la viscosupplementazione basato su di un nuovo materiale a matrice 
polisaccaridica. Il prodotto in esame è un composto di polimero e gel di CMCA 
(carbossimetil cellulosa ammidata) da utilizzare come dispositivo per la 
viscosupplementazione nell’artrosi del ginocchio per ripristinare la funzione di 
lubrificazione e di shock absorber che il fluido sinoviale patologico non è più in grado di 
fornire. 
La parte iniziale del lavoro è stata incentrata sulla caratterizzazione dei processi 
produttivi; dato che il processo di sintesi del prodotto era già stato sviluppato ed 
ottimizzato, sono state messe a punto ed ottimizzate le lavorazioni successive ovvero il 
riempimento del composito all’interno delle siringhe, il confezionamento e la 
sterilizzazione.  
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L’analisi delle proprietà chimiche, meccaniche e reologiche ha costituito una parte del 
lavoro svolto; grazie allo sviluppo di test mirati, come l’analisi attraverso lo 
spettrofotometro IR, il pH-metro, il densimetro ed il reometro, è stato possibile valutare 
le caratteristiche del prodotto fornendo sia un sistema di controllo in produzione che sul 
prodotto finito. E’ stato anche sviluppato uno studio sulla stabilità del prodotto grazie ai 
dati forniti da esame di tipo reologico su campioni di prodotto sottoposto ad 
invecchiamento a temperatura ambiente e ad alta temperatura, simulando un 
invecchiamento accelerato. 
Al termine di questa fase di sviluppo di metodi di controllo dei processi, sul prodotto è 
stata svolta un’analisi di performance tramite test di usura su protesi, in diversi 
accoppiamenti articolari eseguiti in simulatori di passo di anca e ginocchio. Al termine 
del test è stato possibile valutare il livello di protezione fornito dal dispositivo in esame, 
tramite l’analisi dell’usura dei componenti in polietilene (UHMWPE) confrontandola con 
quella subita da liners identici ma che avevano lavorato in presenza di siero bovino.  
Con lo scopo di valutare un possibile ulteriore utilizzo del composto di polimero e gel di 
CMCA è stato sviluppato un ulteriore test utilizzando un simulatore di passo con protesi 
d’anca caratterizzate dall’accoppiamento metallo-metallo. Si è andati così a valutare se 
l’iniezione del prodotto, nel caso di pazienti con protesi in Co-Cr-Mo, sia in grado di 
ridurre il rilascio di ioni metallici, la cui presenza è stata analizzata all’interno del fluido 
lubrificante usato (composto polimero-gel di CMCA o siero bovino).  
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CHAPTER 0: INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
The present thesis work is the result of four months of internship in the R&D 
department of Lima Corporate s.p.a, located in Villanova di San Daniele del Friuli (UD), 
Italy, which is an Italian multinational company specialized in orthopedics and 
traumatology. The core business is focused on the production and distribution of 
implantable prosthesis for knee, hip and shoulder and on research of new materials.  
This project is part of a R&D program that is targeted to the realization of a device for 
viscosupplementation based on a new technology.  
The product herewith described is a CMCA (amidated carboxymethyl cellulose) polymer-
gel dispersion, used to reduce pain in the treatment of osteoarthritis by improving 
mechanical, and rheological behaviour of the synovial fluid; at present, this device is 
concluding the validation phase and it is going to be evaluated in a clinical trial on 
humans.  
Because the production process was already defined and validated, this thesis had been 
focused on optimization and characterization of the processes, i.e. filling, packaging and 
sterilization that have been outsourced.  
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The thesis is oriented to the development of the manufacturing and control processes 
including the analysis of mechanical, rheological, chemical and stability properties of the 
CMCA polymer-gel solution for viscosupplementation in relation to the production 
process and the intended use. Almost all the tests described have been performed 
internally, with the exception of the rheological characterization that has been 
performed in collaboration with Department of Industrial Engineering and Information 
Technology of Trieste. 
Figure 0.1 presents the production flowchart of CMC powder amidation to the final 
product storage. 
Moreover, an analysis of the contest in which the material has to be used has been 
performed: the viscosupplementation technique in the osteoarthritic knee. According to 
this overview, the mechanism of action of viscosupplements has been investigated; then 
the characteristic properties, that are critical for such devices to be effective, have been 
evaluated on the new product.  
The technique has been described with related advantages and disadvantages, reporting 
data from different studies aimed to investigate its efficacy and safety in treating 
osteoarthritic disease.  
The CMCA composite material has been compared to other commercial products, giving 
evidence of the structural differences in the origin, in the biocompatibility and in the 
rheological response as the rationale for the development of this product. 
Particular attention is given to the manufacturing process in all its phases, from raw 
material control, packaging, sterilization and storage of the final product (because of 
their great importance in determining product properties) and its aging.  
As to shelf life evaluation, a study was performed in order to understand product 
properties trend by measuring two parameters: Elastic and Viscous Moduli, in a 
frequency range between 0,02Hz and 10Hz. This study allowed to predict how this 
characteristics change in time and how fast they do it, comparing real time aging and 
accelerated aging, obtained by high temperature exposition. Another important 
information that can be obtained from this study, once defined the acceptable variation 
range of the analyzed properties, is the product’s shelf life.  
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Finally, three experiments that exhaust the wear of prosthetic implants in presence of 
CMCA polymer-gel dispersions are presented. The first simulates the lubricating action 
in the knee by the use of a machine reproducing the movement of this joint. The second 
analyzes the effects of the presented product, in presence of Metal on Metal (MoM) 
total hip prosthesis: this test also allowed verifying the ion release, connected to the 
wear of the Cr-Co-Mo prosthesis in the presence of the CMCA polymer-gel mixture.  
The three mechanical tests, due to their complexity, have been carried out with the 
project management approach in order to have the possibility to control, handle and, if 
necessary, to re-organize activities in the best way. 
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Figure 0.1 
Production Process 
CMC raw material 
CMCA Polymer Synthesis 
CMCA Polymer Purification 
CMCA Polymer Freeze-Drying 
CMCA Polymer Milling 
CMCA Gel Synthesis 
CMCA Gel Purification 
CMCA Gel Freeze-Drying 
CMCA Gel Milling 
CMCA Polymer & Gel Hydration and 
Blending 
Syringes Filling 
Moist Heat Sterilization 
CMCA Composite Analyses 
Product Storage 
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CHAPTER 1: VISCOSUPPLEMENTATION 
 
 
 
 
 
 
 
 
 
 
 
1.1 OSTEOARTHRITIS AND VISCOSUPPLEMENTATION 
Osteoarthritis (OA) is a chronic degenerative multifactorial joint disease characterized by 
a progressive degradation of the articular cartilage, a drop in the articular joint space, 
subchondral sclerosis, cysts, synovial inflammation and osteophyte formation [1]. It is 
the most widespread form of joint disease and it has been worldwide estimated that 
9,6% of men and 18,0% of women older than 60 years suffer of OA [2]. 
 
a.   b.    
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c.   d.  
Figure 1.1  
OA progression from a normal joint (a.) to a severe OA  
with drop in articular joint space and osteophytes formation (d.) [3]. 
 
The knee is a joint where OA is quite common because of aging. Figure 1.1 shows the OA 
progression in the knee from a normal joint (a) to a severe OA (d) in which the articular 
joint space is reduced and the formation of osteophytes is visible. Diarthrodial joints, 
also known as synovial joints, such as the knee, are those which can move more freely 
and contain synovial fluid. Normal synovial joints essentially provide frictionless motion 
between limb segment and they are characterized by a very low friction coefficient 
between articular cartilage surfaces, in healthy conditions, due to the presence of the 
synovial fluid. Diarthroid joints operate well under a wide range of conditions from low 
loadings and high shear rates to high loadings and low shear rates. 
Synovial fluid (SF), or synovial, is a clear viscous liquid fluid, secreted by synovial lining 
cells, that occupies joint’s cavity with its lubricating and nutritive action. It supplies 
nutrients, necessary for chondrocyte metabolism, and removes catabolic products since 
normal articular cartilage has no blood supply. The primary role of SF is protective, by 
limiting axial forces on the articular surfaces and decreasing friction between joint 
surfaces [1]. 
The most abundant macromolecules in synovial fluid are sodium salt of hyaluronic acid 
(NaHA in a concentration of  3,5 mg/ml and a high average molecular weight) and blood 
plasma proteins (10-30mg/ml) as albumin (8-13mg/ml) [4].  
Hyaluronic Acid (HA) is a very long chained (between 3 and 30µm) unbranched non-
sulfated GAG made by the repetition of a disaccharide unit of N-acetyl-glucosamine and 
residues of glucuronic acid linked with a glicosidic bond (see Figure 1.2).  
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Figure 1.2 
The disaccharidic unit (glucuronic acid and  N-acetilglucosamine)  
repeated in the main structure of HA. 
 
HA, which is the most abundant glycosanminoglican  (GAG) in mammalian tissue and in 
diarthroid, in healthy joints reaches the concentration of about 0,5-4mg/ml essential for 
normal joints functions.  
The presence of Hyaluronic acid (hyaluronan) governs synovial fluid’s viscous and 
lubricant behaviour. It also bonds the opposing surfaces of the joints to each other 
creating a tensile strength enabling opposing surfaces to slide freely across each other 
and limiting their separation. Synovial fluid’s lubricating and chondroprotective ability is 
not entirely dependent upon viscosity but also to its ability to change physicochemical 
nature of a surface, repelling one to another in a process called “boundary lubrication”. 
This process is mediated by the lubricin which is a synovial fluid glycoprotein [5]. 
Hyaluronic acid, instead, is responsible for synovial fluid’s rheological properties, 
enabling it to act as a lubricant or shock-absorber [6].  
Considering the knee joint, the volume of synovial fluid contained is well documented in 
literature as shown by the following chart. 
 
SOURCE JOINT VOLUME 
[7] All synovial joints even the largest < 2 ml 
[8] Generic joint cavity considering type and 
inter-individual variability 
[0.1-4] ml 
[9] Not specified < 4 ml 
[10] Not specified ≤ 3.5ml 
[11] Knee [0.13-3.5] cm3  average 1.1 cm3 
[12] Knee  ≤ 3.5 ml  average 1ml 
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[13] Knee ≤ *3-4] ml 
[14] Knee ≤ 5 ml 
[15] Knee [0.5-1.5] ml 
[16] Knee [0.5-4] ml 
[17] Knee [0.3-1] ml 
[18] All synovial joints even knee < 3 ml 
[19] Synovial joints ≈ 3 ml 
[20] All synovial joints even the largest [0.2-0.5] ml 
[21] Knee ≤ 4 ml 
[22] Knee ≤ 4 ml 
[23] Knee ≤4 ml 
[24] Knee [0.5-4] ml 
Table 1.1 
Synovial Fluid Volume and References 
 
In osteoarthritis, the synovial fluid is more abundant and less viscous in fact hyaluronan 
becomes depolymerised and its concentration and molecular weight (MW) are reduced 
causing a drop in elastoviscous properties [1,6]. These changes increase cartilage 
susceptibility to injuries and damage. 
 
 
Figure 1.3 
Agarose gel electrophoresis of Normal and OA Synovial Fluid [25] 
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The polydispersity profile of hyaluronan in osteoarthritic fluid is more variable than in 
healthy patients as it could be seen in Figure 1.3; however it always contains a small 
variable amount of high molecular mass fraction (>2 million Da) [25]. 
Viscosupplementation by repeated intra-articular injections of viscoelastic solutions is 
used in the treatment of symptomatic knee osteoarthritis. Viscosupplement usually 
injected are exogenous HA or its derivatives: they decrease pain and improve knee 
functions through the restoration of the synovial fluid’s rheological properties. 
 There are different injection techniques that differ by knee position (bent, straight or 
partially bent) and injection site (infra-pattellar, medial or lateral) and the choice is 
made by the physician depending on his experience and on the patient. The technique 
does not influence so much the onset of adverse effects although knee partially bent 
reduces them [2,6]. 
The first evidence that joint injections of hyaluronan could reduce pain was given by 
Balazs et al. in 1960s. They used hyaluronan solutions made of highly purified Na-
hyaluronan of relatively high MW (>2million Da) in concentrated (1%) solutions 
(dissolved in phosphate-buffered physiological NaCl). The hyaluronan was taken from 
human umbilical cord or rooster comb and was sterile, pyrogen-free and caused no 
inflammation while injected into various tissues and tissue spaces of animals such as 
vitreous, joints and peritoneal cavity. This highly purified fraction with only traces of 
protein was non-immunogenic and was called the “non-inflammatory fraction of Na-
hyaluronan” (NIF-NaHA). The first preparation made for medical use was called with the 
trade name Healon® (Biotrics, Arlington, Mass., USA, 1972) [25]. 
In early 1970s viscosupplementation with hyaluronan was used to reduce pain of racing 
horses [26]. In 1987 hyaluronan solutions were approved for the treatment of arthritic 
pain in Japan and Italy and in 1997 they were approved by Food and Drug 
Administration (FDA) [1,27]. 
Hylans are cross-linked forms of purified hyaluronan with extremely high molecular 
weights (about 6million Da) developed to obtain solutions with greater viscoelastic 
behaviour without affecting the two specific groups of the molecule [26,28]. The aim to 
produce high molecular weight and high concentrated products is due to the greater 
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analgesic effect they obtain after injection. Because of their greater viscosity, crosslinked 
hyaluronans prevent their removal from the synovial cavity increasing their residence 
time [5]. 
The therapy’s analgesic effect is thought to be achieved by multiple mechanisms as for 
example the reduction of pain provided by the creation of a viscoelastic protective 
barrier around the nociceptive afferent fibers in the intercellular matrix [6,27,29]. It has 
been demonstrated that a mechanical stress can induce stretch-activated ion channels 
opening in cellular membrane and that their activity can be reduced if cell membrane 
are bathed in elastoviscous hylan solutions [25]. There are some sensory endings in 
direct contact with the hyaluronan-rich extracellular matrix so a change in elastoviscous 
properties (caused by concentration or MW variations) can influence the sensitivity of 
these terminals to mechanical and chemical stimuli [25].  
Studies on cats demonstrated that injection of elastoviscous hylan in the inflamed knee 
joint significantly reduces the inflammation-evoked ongoing and movement-evoked 
nerve discharges. Non-elastoviscous hylan does not produce this effect. 
The attenuating effect of hylan on nociceptive afferent discharges cannot be explained 
by the volume increase caused by the injected fluid, because this effect could never be 
obtained with the same volume of nonelastoviscous hylan. Most importantly, the 
nonelastoviscous hylan solutions contain the same concentration of chemically identical 
but smaller molecules of hylan than the elastoviscous hylan solution. The difference in 
mean molecular weight results in differences in physical (rheological) properties. This 
strongly indicates that different effects are related to the viscoelasticity of the solution. 
The lack of effect of nonelastoviscous hylan cannot be explained by differences in 
diffusion in the joint, because, at the time of measurement (1–2 h after injection), these 
molecules are still present in the joint. The reduction of nociceptive discharges in 
articular afferent fibers by elastoviscous hylan solutions described in the present study 
provides experimental support to the clinical observation that viscosupplementation 
with elastoviscous hyaluronan and hylan solution decreases pain and improves the 
mobility of joints in race horses with traumatic arthritis and in osteoarthritic human 
knee [30]. 
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Another advantage of viscosupplementation is that the injection of hyaluronan or hylan 
stimulate synovial cells to synthesize endogenous, high quality, hyaluronic acid giving a 
very long efficacy to the treatment, also exceeding resident time of the injected product 
in the joint [6,29,31]. 
OA causes motility problems such as slow speed, limited peak knee flexion and 
extension degrees, decreased weight bearing that could be improved with intra-articular 
injection of hylan inducing an alteration on the natural history of the disease by 
decreasing excessive loading in the knee [31]. 
The American College of Rheumatology suggests an initial non-operative, non-invasive 
treatment of OA consisting in physical therapy and weight loss followed by 
pharmacological intervention including topical and oral analgesics, non steroidal anti-
inflammatory drugs (NSAIDs), opioids and steroids. The long-term use of these 
pharmacologic agents can induce deleterious effects and some patients may have 
gastrointestinal or renal intolerance of NSAIDs. Considering this, viscosupplementation 
provides a pharmacologic alternative for who is functionally limited, due to 
osteoarthritic knee pain, especially for those who wish to postpone surgical intervention 
or for whom this solution is inappropriate [32].  
The viscosupplementation technique is not free of local adverse events (AEs) which are 
the same observed with other intra-articular injections including corticosteroids as well 
as saline [33,34]. The etiology and pathophysiology of these local AEs is not clear but it 
has been hypothesized a connection with the procedure, the sensitivity of synovium, the 
disease stage of process, the inflammatory reaction to the product, patient activity after 
the treatment, age, time since diagnosis, infection or allergy to avian products [2,33]. 
However most adverse events reported in literature are minor and transient at the 
injection site. Painful post-injection reaction occurres in 1-2% patients and it do not last 
more than 72 hours. Systemic allergic reactions due to individual hypersensitivity were 
rarely recorded [28]. 
Improper intra-articular needle placement is thought to cause local tissue damage, pain 
and swelling for example in the case of injection into the perisynovial fat pad but, if 
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correctly executed, the injection technique does not influence the possibility to 
experience AEs instead [2,33].  
Concluding, viscosupplementation has been demonstrated to be effective in reducing 
pain connected to OA and also in improving motion ability and to stimulate new 
production of healthy HA. These effects are much more greater in underweight patients, 
in males and in patients more recently diagnosed of OA  
 
1.2 COMMERCIAL PRODUCTS 
There are many commercial HA preparations available for viscosupplementation; they 
have animal or synthetic origin and they can be based on hyaluronic acid (or its 
derivatives) or not. Most are hydrogel formulations of HA in water for injection and may 
contain addition excipients such as sodium chloride for isotonization and sodium 
hydrogenphosphate for pH adjustment. Most contain low molecular weight HA (0,5-1,5 
million Da) while one formulation (Synvisc®) contains cross-linked HA (hylan) with 6-7 
million Da molecular weight [4]. 
The animal origin, usually by isolation from rooster comb or by fermentation (e.g. 
Streptococcus equii), can induce allergic reaction, due to the presence of protein traces, 
if injected in sensitive people. Moreover, cellulose derivatives are characterized by  
great similarity in mechanical, chemical and rheological properties to human hyaluronic 
acid. 
This similarity is the final goal of all commercial products because it is the key to 
properly act after injection, reducing the pain and affording mechanical stress. 
Synovial fluid is characterized by both elastic and viscous properties depending on size, 
conformation, interaction and number of hyaluronic acid molecules in the fluid. The 
elastoviscous characteristic can be detected through the dynamic shear modulus (or 
dynamic rigidity G*) measured at various frequencies. It can be splitted into its two 
components: the elastic modulus G’ and the viscous modulus G’’ (Equation 1.1).  
G* is the ratio between the peak stress to the peak strain considering a sinusoidal 
solicitation (Equation 1.2). 
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Equation 1.1 
Dynamic Rigidity components 
 
   
     
     
 ;  
Equation 1.2  
Dynamic Rigidity Definition 
 
G’’ is also called dynamic loss modulus since it is connected with the energy dissipated 
as heat when a strain is applied; G’ is also known as storage modulus and represents the 
energy stored during strain. 
While increasing strain frequency the synovial fluid rapidly transits from a viscous to an 
elastic body. This transformation is reversible and has no deteriorating effect on the 
molecules.  
 
 
Figure 1.4 
Elastic modulus (G’) and viscous modulus (G’’) of synovial fluid. 
(Balzas et al.) [35] 
 
As can be seen in Figure 1.4  OA is a pathologic condition in which both moduli have a 
lower value and G’’ is always greater than G’. The viscosupplementation technique aims 
at restoring a situation much more similar to the healthy one. 
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In 1997 in the USA Hylan G-F 20 (commercial name Synvisc®) was approved as a VS 
product. It is a high molecular weight HA derivate composed of two hylan polymers 
within a buffered physiological NaCl solution. The first polymer called hylan A is native 
hyaluronan which is soluble and with high MW; the second polymer is hylan B that is an 
insoluble gel. The crosslinking between the two molecules produces a product with very 
high MW (6 million Da) and creates a continuous molecular network. Hylan G-F 20 is 
non-immunogenic, non-inflammatory and does not cause foreign-body reactions [1,27]. 
Other products available are for example Orthovisc® (1,2 million Da [25]) and Ostenil® 
both medium molecular weight hyaluronan but it has been demonstrated that lower 
MW HA present lower values for G’ and G” in fact Hylan G-F 20 presents greater 
elasticity and viscosity at all frequencies [26]. 
 
 
Table 1.2 
Comparative elastoviscosity of hylan G-F 20 and that of lower-molecular-weight (LMW) 
hyaluronan [26]. 
 
The fact, highlighted in Table 1.2, is that high molecular weight hyaluronans present 
higher values of both moduli at the considered frequencies, showing, in this range, 
superior viscoelastic properties. This consideration is sustained by the fact that patients 
treated with higher MW hyaluronan feel a greater improvement in weight-bearing pain 
from the initial condition before treatment [26]. Hyalgan® (0,5 million Da) is another 
product for VS but due to its low molecular weight does not produce any effect. 
Orthovisc® with its medium MW induces some improvements but they last for a lower 
period than Synvisc® [25]. 
Table 1.3 presents some hyaluronic acid commercial products for viscosupplementation 
with their MW, and origin. 
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Table 1.3 
MW of some hyaluronic acid products [28]. 
 
An alternative to hyaluronan and its derivatives is an innovative product derived from 
cellulose. In particular it is an amide carboxymethyl cellulose amide (CMCA) in which the 
amidation has been introduce to improve the biocompatibility creating a  cellular 
structure more similar to hyaluronic acid that encourages cell proliferation. CMC is the 
most common cellulose derivative and it is made of a long polymeric chain of repeated 
units of D-glucose. The CMCA constitutes the polymer part (up in Figure 1.5) while the 
crosslinked CMCA forms the gel (down in the Figure 1.5). 
 
 
Figure 1.5 
CMCA composite: Polymeric part (at the top) and gel part (at the bottom). 
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The result is a non-Newtonian viscoelastic system composed by two polymeric 
components: CMCA crosslinked gel dispersed in a polymeric solution of linear CMCA in a 
volume of saline sufficient to reach the desiderated concentration. 
Another important characteristic that have to be considered while designing a 
viscosupplement is its degradation behaviour. In fact it has to be introduced in an 
ambient rich of enzymes able to cleave its chemical bonds affecting its chemical and 
mechanical properties. Two enzymes that are present in synovial fluid are for example 
lysozyme and hyaluronidase. Lysozime (LZM) is a single chain protein with a MW of 14,3 
KDa which catalyzes the hydrolysis of β(1-4) link between N-acetilmuramic acid and N-
acetylglucosamine. The synovial fluid concentration of LZM has been determined by 
Klockars M. et al. who found that the mean concentration in osteoarthritic patients is 
similar to the one of healthy patients [36]. Hyaluronidase  is an hydrolitic enzyme that 
separates hyaluronic acid in its fundamental components (D-glucuronic acid  and N-
acetyl-D-glucosamine). Comparing hyaluronic acid and the CMCA polymer-gel solution 
their weight loss was monitored after exposing their freeze-dried form to the degrading 
solution (hyaluronidase at the concentration of 0,1U/ml or lysozyme at the 
concentration of 37,73 UI/ l in accord with physiological conditions). After 7 days in 
hyaluronidase solution the CMCA preparation and hyaluronic acid lost 15,8% and 40% 
respectively; at the 28th day CMCA losts only 38% while hyaluronic acid losts even 81%. 
In lysozyme solution CMCA and hyaluronic acid lost 20% and 15,3% respectively, in 7 
days; in 28 days they lost 40% and 43% respectively [37]. The resistance to enzymatic 
degradation is an important characteristic due to the fact that it allows the product to 
withstand into the biological environment.    
The number of injections for a complete treatment, is strictly related to the particular 
product, the volume contained in the syringe, its molecular weight and its 
concentration. Most formulations propose a dosage of three injections of 2ml, one at 
week. It has been demonstrated that several injections can increase the intensity of 
adverse effects to the treatment [34]. The incidence of AEs was found to present an 
approximate two-fold increase in incidence compared in patients previously exposed to 
hyaluronan or hylans. The mechanism for an increased incidence of local adverse events 
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in those with previous treatment is not totally known but it is supposed to have an 
immunologic basis [2]. 
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CHAPTER 2: MANUFACTURING PROCESSES 
 
 
 
 
 
 
 
 
 
 
 
2.1 PRODUCT PROCESSING 
The product manufacturing consists in a series of consequent phases strictly connected 
one to each other in a temporary order. The flow chart, hereinafter reported, presents 
all  these activities for the processing of the CMCA composite material. 
 
 
Figure 2.1 
Manufacturing Process flow chart. 
 
Each phase will be described in the following Paragraphs with the tests that allowed to 
consider them a good practice to obtain an effective and safe product. The process 
starts with the freeze-drying of the material that, after this, is milled and delivered to a 
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subcontractor to be filled in the syringes and sterilized; after sterilization the material is 
sent back to Lima Corporate S.p.a, analysed and then stored.  
 
2.2 HYDRATION 
The CMCA polymer and the CMCA gel, once produced, are freeze-dried, milled 
separately, and stored. For the production of the composite material the two freeze-
dried powders are mixed, hydrated and filled in syringes of 4ml.  The  filling procedure is 
a process carried on by a subcontractor that has a semi-automatic filling process for the 
filling of high viscous suspensions and gels. 
Two critical points connected with the hydration process are the final solution 
concentration and the non pyrogenicity. To assure this two characteristics, the 
corresponding tests were performed. In Paragraphs 2.2.1 and 2.2.2  they are described 
with the procedure adopted and the results obtained.  
 
2.2.1 Density Test 
A density test has been designed and performed in order to control the correct 
hydration concentration; in fact density is a parameter that changes as the 
concentration does and it is measured by a density meter. The densimeter is composed 
of a U-shaped borosilicate glass tube in which the sample is introduced (only 1mL is 
needed) with a syringe.  
 
 
Figure2.2 
The density meter analyzing the content of the syringe. 
 
When in use, the tube containing the product is excited to vibrate due to a magnetic 
domain; the characteristic frequency changes depending on the sample’s density. If the 
A New Device for Viscosupplementation Treatment: Development of Manufacturing and Control 
Processes 
 
 
27 | 
 
tube is filled only with air, the oscillatory frequency is checked to correspond to the 
harmonic oscillation at the fundamental frequency of 440 Hz.  
Due to the temperature dependency of the density value, a precise temperature control 
of the sample is required and measures have to be done at the same temperature 
(20°C). Density values measurable with the instrument range are from 0 to 3 g/cm3 and 
results are affected by a very little error (about 0,001 g/cm3). 
In order to find the relationship between concentration and density, a series of tests 
have been done. The first test consisted in measuring the density of different samples of 
the CMC raw material dissolved in water solution at different concentrations (0,1%, 
0,5%, 1,0%, 1,5% and 1,7% W/W). The second test was the same but the samples 
analysed were of CMCA polymer diluted in water at 0,1%, 0,5%, 1,0%, 1,5%, 1,6%, 1,7%, 
1,8% and 2,0% W/W. For each concentration, several measures were taken in order to 
calculate an average value (SD are reported in brackets). Table 2.1  shows the average 
density values measured, both for CMC and CMCA polymers. 
 
CONCENTRATION 
% 
CMC Density 
[g/cm3] 
CMCA Density 
[g/cm3] 
0,1 0,9986 (0,0002) 0,9982 (0,0004) 
0,5 1,0003 (0,0002) 0,9993 (0,0007) 
1,0 1,0027 (0,0002) 1,0015 (0,0001) 
1,5 1,0049 (0,0007) 1,0032 (0,0001) 
1,6 - 1,0036 (0,0001) 
1,7 1,0058 (1,0003) 1,0037 (0,0001) 
1,8 - 1,0041 (0,0000) 
2,0 - 1,0050 (0,0001) 
Table 2.1 
CMC and CMCA densities at different concentrations. 
 
From these values, two linear relationships were obtained and their expressions are 
reported below: 
 
                 
Equation 2.1 
CMC densities tendency line. 
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Equation 2.2 
CMCA densities tendency line. 
 
The following graphs present the linear relationships described; density is plotted vs 
concentration. The sample’s values are represented in blue while the violet lines in 
Figure 2.2 and Figure 2.3 are Equation 2.1 and Equation 2.2 respectively. 
 
 
Figure 2.3 
CMC polymer densities at different concentrations and tendency line.  
 
 
Figure 2.4 
CMCA polymer  densities at different concentrations and tendency line. 
 
The same test has been performed on seven samples of CMCA composite material, 
internally prepared, not with the automatic technique performed by the subcontractor, 
and filled at 1,00%, 2,00%, 3,5%, 3,61%, 3,71%, 3,80% and 4,00% W/W in saline solution. 
For each concentration a minimum of three measures were done and the average 
values, presented in Table 2.2, were used to find out the tendency line (see Equation 
2.3). The values in brackets in Table 2.2 are the standard deviations obtained. 
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CONCENTRATION 
% 
CMCA Mixture 
Density [g/cm3] 
1,0 1,0073 (0,0004) 
2,0 1,0105 (0,0001) 
3,5 1,0150 (0,0006) 
3,61 1,0157 (0,0001) 
3,71 1,0158 (0,0003) 
3,8 1,0164 (0,0001) 
4,0 1,0169 (0,0003) 
Table 2.2 
CMCA Mixture densities at different concentrations. 
 
                
Equation 2.3 
CMCA Mixture densities tendency line. 
 
Figure 2.4,shows Equation 2.3 in violet and the average values reported in Table 2.2 in 
blue. The value plotted in yellow is the average value obtained from a sample of CMCA 
composite material filled with the automatic filling technique, using nitrogen as 
propellant gas, in a 3,71% saline solution (in the next Paragraph the reason connected to 
the choice of nitrogen for the standard procedure is discussed). 
 
 
Figure 2.5 
CMCA composite densities at different concentrations. 
 
As it can be seen, the tendency line fits well also for the value obtained from a sample 
prepared using nitrogen, giving evidence to the fact that Equation 2.3 describes the 
relationship between concentration and density for a CMCA sample without caring on 
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the filling technique in fact the automatic filling (yellow sample in Figure 2.5) and the 
internal procedure (blue samples in Figure 2.5) present the same trend. The correlation 
between the values reported and the line is 0,999 showing the great agreement found. 
Comparing the three lines obtained (for CMC and CMCA polymers and for CMCA 
composite material) it is clear that they are very similar and the fact is highlighted by the 
correlation coefficients: 
 
 CMC - CMCA polymers: 1,000 
 CMCpolymer - CMCAcomposite: 0,999 
 CMCApolymer - CMCAcomposite: 0,999 
 
These density tests allowed to obtain the linear relationship between density and 
sample’s concentration giving the possibility to perform two controls: 
 
1. Process Control to verify the correct concentration of the CMCA polymer before 
starting its freeze-dry process and the synthesis of the CMCA gel. 
2. Final Product Control to verify that hydration and blending were performed 
correctly. 
 
The control that is performed with the density measure is very accurate in fact it is 
possible to distinguish a difference of 0,1% in concentration. 
2.2.2 Pyrogen Test 
At the beginning of Paragraph 2.2 the problem of pyrogenicity have been presented. To 
avoid the presence of pyrogens in the final product, the hydration of polymer and gel 
powders, obtained after freeze-dry process, is performed in non pyrogen and sterile 
saline solution. The pyrogen test is required for intravenous-injectable products and the 
CMCA mixture, even if it requires an intra-articular and not intravenous injection, has 
been tested and resulted pyrogen free. This test was performed in a worse case 
condition than the condition of intended use. 
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Pyrogens are substances inducing fever response which can be produced by some gram 
positive bacteria, mycobacteria, fungi and also viruses. Pyrogens produced by gram 
negative bacteria, i.e., endotoxins, are important for the pharmaceutical industry [39]. 
There can be several sources of pyrogens in parenteral and medical products and usually 
they are: water used as solvent or for the processing, packaging components, chemicals, 
raw materials or the equipment [39]. 
Non pyrogenicity is a more severe restriction than sterility due to the fact that sterility 
does not mean non pyrogenicity. A sterile product may contain non vital 
microorganisms, or parts thereof (cell wall components as lipopolysaccharides) which 
cannot induce infection but which could induce inflammatory response and fever. This is 
the reason why non pyrogenicity is required for intravenous-injected products. 
Pirogenicity is not only induced by microorganisms, but it could be also caused by 
polysaccharides and other components of medical devices;  this consideration allows to 
distinguish between pyrogenicity of the material itself and pyrogenicity caused by 
contamination. As a consequence a cellulose derivative product such as the CMCA 
composite material, has to be tested. 
The Material Mediated Pyrogen test evaluates the potential of a material to cause a 
pyrogenic response, or fever, when introduced into the blood. Lot release testing for 
pyrogenicity is done in vitro using the bacterial endotoxin (LAL) test and must be 
validated for each device or material. However for biocompatibility assessment, the 
rabbit pyrogen test, is preferred. The rabbit test, in addition to bacterial endotoxins 
detection, is sensitive to material-mediated pyrogens that may be found in test 
materials or extracts. The European Pharmacopeia [40] describes the pyrogen test as a 
measure of the increase of temperature in rabbits due to an intravenous injection of the 
sterile solution of the substance under analysis. The difference between the initial 
temperature and the maximum registered is considered the rabbit’s reaction to the 
injection.  
 
A New Device for Viscosupplementation Treatment: Development of Manufacturing and Control 
Processes 
 
 
32 |  
 
 
Table 2.3  
Evaluation of pyrogen test [40].  
 
The test has to be performed in one group of three animals at least. The test is passed if 
the sum of the reactions, for a specific number of animals (first column in Table 2.3), is 
lower than a specific value (second column) for that number of animals; on the other 
side the test is considered not passed if the sum of the reactions is greater than the 
values in the third column. If the summed reactions is between the values of the first 
and the second column, another group of animals is required and the test is repeated. 
The pyrogen test on the CMCA composite material has been performed by an external 
laboratory which injected 1ml/kg of the product, diluted 1:10 in sodium chloride, into 
the ear vein of three male albino rabbits (white New Zealand rabbits). The product was 
warmed at room temperature before injection and the temperatures of the rabbits were 
recorded at intervals of 30 minutes in the three hours after injection, to individuate any 
temperature raising. The temperature increase was 0,15°C, 0,10°C and 0,55°C and the 
sum of the responses was 0,80°C that is less than 1,15°C (upper treshold to consider the 
test passed in the case of one group of rabbits). This test established that the CMCA 
mixture meets the requirement for the absence of pyrogens. 
 
2.3 PACKAGING AND FILLING TECHNIQUE  
Once hydrated, the product  has to be packed and stored. According to the International 
Standard UNI EN ISO 11607-1 [41] the packaging system provides physical protection, 
maintain sterility up to the point of use and allows identification thanks to appropriate 
labels. The package must be sterilized without degradation and it has to ensure the 
stability of the material till the expiration date guaranteeing  environmental protection 
A New Device for Viscosupplementation Treatment: Development of Manufacturing and Control 
Processes 
 
 
33 | 
 
(barrier from moisture, bacteria, oxygen, light). The package has also to provide dynamic 
protection resisting to impacts, abrasions and to ensure structural support [42].  
The primary packaging of the CMCA composite material is made of a glass syringe and 
the secondary packaging is made of a plastic blister. Due to the fact that in the past it 
was used a plastic syringe and a plastic pouch it was necessary to demonstrate that the 
new package system does not influence the product’s characteristics, both physical and 
chemical, making a new validation. The reason why the glass syringes are preferable to 
the plastic ones is the better storage characteristics. 
 
          
Figure 2.6 
The glass syringe in the plastic blister (left) and the plastic syringe in the plastic pouch. 
 
To evaluate if the new syringes influenced the material characteristics an infrared (IR) 
spectroscopy and a pH analysis were done. A viscosity measure was added to find out 
the effects of the use of air or nitrogen, as propellant gas, in the automatic filling 
technique. 
2.3.1 Techniques Description  
Infrared (IR) spectroscopy is an established technique used for structural investigation 
and compound identification. Basically, it is the absorption measurement of different IR 
frequencies by a sample positioned in the path of an IR beam. The main goal of IR 
spectroscopic analysis is to determine the chemical functional groups in the sample,  
absorbing at characteristic IR frequencies. The spectrum is usually given as a 
transmittance (T) measure that is the fraction of incident light, at a specific wavelength, 
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that passes thought the sample. The absorbance (A) is the logarithm of the 
transmittance’s inverse.  
 
  
 
  
 
Equation 2.4 
Transmittance Definition 
 
      
  
 
           
Equation 2.5 
Absorbance and Transmittance Relationship 
 
where I0 is the intensity of incident radiation and I the intensity of the radiation coming 
out of the sample [40]. 
The resolution for the wave length is 4 cm-1 and the range analysed in the experiments 
presented is between 4000 and 450 cm-1.  
The pH measure is an electric potential measure reported in pH units. The instrument’s 
probe measures the electric potential with the glass probe containing a silver chloride 
electrode. The measure is expressed in relation to the known pH of a solution. The pH 
has to be measured at the same temperature (chosen between 20°C and 25°, in our case 
20°C) [40]. 
 
 
Figure 2.7 
Vibro Viscometer SV-10 used in the test. 
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Figure 2.7 shows the vibro viscometer used to measure the viscosity in this test. The 
instrument relats viscosity to the measure of the opposition to the movement induced 
by the fluid to the vibration of the sensor plates. This constant vibration is driven by an 
electric current which induces a constant sine-wave vibration at 30Hz. The viscometer is 
equipped with a temperature sensor allowing measures between 10°C and 40°C. 
The packaging study has been performed over two samples: the first was the product 
stored in the plastic syringe and the second in the glass one. 
2.3.2 Plastic and Glass Syringes Comparison 
First of all a spectrometric valuation of the samples has been performed so two IR 
analyses were done (one for each sample). A little part of the content of each syringe 
has been analysed. For each sample, 8 measures (resolution 4,00 cm-1) were collected 
and the results were averaged. This choice results in measures with a good accuracy.  
The strong similarity in the spectra of the samples analysed confirms that the differences 
in materials composition have no influence in the chemical structure. Comparing the 
two spectra was clear that the only one difference was in the intensity of the peaks 
giving evidence that glass does not induce chemical changes in the product. 
Figure 2.8 shows the great agreement existing: it can be confirmed also by the 
correlation factor between the two spectra (0,9809).  
 
 
Figure 2.8 
Spectrum of the product contained in the plastic syringe (in blue) and in the glass one (in red). 
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The pH measurements have been done for each sample and the values obtained are 
reported in Table 2.4, showing a great similarity. These results corroborated the 
conclusions obtained from the IR analysis giving a new proof of them. 
 
SAMPLE pH 
Plastic Syringe 4,65 
Glass Syringe 4,68 
 
Table 2.4 
Values of pH for plastic and glass syringes 
 
From these results it was clear that glass syringes do not cause chemical or physical 
changes in the product ensuring a safe use as plastics did. 
2.3.3 Propellant Gasses Comparison 
In order to prevent possible oxidation caused by oxygen, used as the propellant in the 
filling technique, it was hypothesized to use an inert gas (nitrogen). The comparative 
analysis was done to check if the gasses used were safe, efficient or changed chemical 
and physical properties of the material. IR analysis, pH and viscosity measurements were 
done with the aim to evaluate any possible changes. 
All the tests have been performed on three syringes over two sets: Set One, referring to 
syringes filled in oxygen, and Set Two, filled with nitrogen. The samples were 
autoclaved, before performing tests, using three different sterilization cycles (named 1, 
2 and 3, respectively) which specimens are reported in the Paragraph 2.4. 
Figure 2.9 shows all the spectra obtained, one for each sterilization cycle and gas used. It 
is clear that they do not influence the chemical structure of the material. Comparing 
only couples of spectra of the same sterilization cycle, it is evident that the filling 
technique does not induce any chemical change on the product. 
Considering pH and viscosity measures the results obtained are presented in Table 2.5 
where it is shown that pH values are all similar giving strength to the conclusions gained 
with the IR analysis. The viscosity analysis allowed to understand that the oxygen filling 
technique induces a greater drop in the viscosity. 
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Figure 2.9 
Spectra from six different syringes filled in oxygen (red, light-blue, black) or nitrogen 
(green, blue, violet)and sterilized with Cycle 1 (red, green), Cycle 2 (light-blue, blue), 
Cycle 3 (black, violet). 
 
This consideration gives evidence that nitrogen filling is better: preserving viscosity is 
very important in relation to the intended use of the product as a viscosupplement for 
osteoarthritis. 
 
SAMPLE pH VISCOSITY [mPa*s] 
1-Oxygen 4,68 918 
2-Oxygen 4,61 947 
3-Oxygen 4,70 1020 
1-Nitrogen 4,65 1825 
2-Nitrogen 4,78 1835 
3-Nitrogen 4,69 1841 
Table 2.5 
Values of pH and viscosity of the six samples. 
 
In conclusion, this experiment allowed to affirm that from the chemical point of view the 
switching from air filling to nitrogen does not induce any chemical modification of CMCA 
polymer and gel. The only modification that can be observed is in terms of mechanical 
stability increase, as viscosity values demonstrate.  
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Considering that nitrogen is an inert, nontoxic gas, widely used in the pharmaceutical 
industry, it can be assumed that filling with N2 does not influence the safety of the  
CMCA composite material, indeed it represents an ameliorative method to preserve 
mechanical properties.   
 
2.4 STERILIZATION PROCESS 
The product in its packaging must be sterilized to guarantee sterility which is a 
fundamental characteristic for medical devices. In this Paragraph the method used to 
sterilize the product is described with all the parameters considered to find out the most 
effective cycle, to assure sterility, and not damage mechanical properties. In order to 
develop the most adapt sterilization procedure three different sterilization cycles were 
developed and tested in order to find out their effects on mechanical and rheological 
properties. To verify these effects the rheological tests were performed in order to 
compare the values of the elastic and viscous moduli between the samples treated with 
the different cycles. 
Sterile means that the product is free of viable microorganism [43-45] because the term 
“sterile” is applied to pharmaceutical products that have been treated (sterilized) in the 
way that, at the end of the process, individual items have a probability of being non 
sterile or have a sterility assurance level (SAL) equal to 1x10-6 [43,46,47,48]. The term 
bioburden is used to mean the population of vital microorganisms present in or on a 
product or barrier system. It comes from a sum of different sources including, in the 
most general case, raw materials, manufacturing, assembling processes and 
environments, cleaning and packaging and latter aids like compressed gasses, water and 
lubricants. The purpose of sterilization is to inactivate the microbiological contaminants 
and thereby transform a non-sterile products into sterile. The kinetics of inactivation of 
a culture of microorganisms by physical and/or chemical agents used to sterilize medical 
devices can generally be described by an exponential relationship between the numbers 
of microorganisms surviving and the extent of treatment with the sterilizing agent (see 
Equation 2.6); therefore, there is always a finite probability that a microorganism may 
survive regardless to the entity of the treatment. 
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Equation 2.6 
Kinetics of inactivation of a culture of microorganisms by sterilizing agents. 
 
Nt is the number of surviving organisms after time t, N0 is the number of microorganisms 
at time zero (bioburden), t is the exposure time and k is a microbial inactivation rate 
constant. This expression represents a firs-order kinetic process (see Figure 2.10). 
 
 
Figure 2.10 
Number of surviving microorganisms after sterilization treatment [49]. 
 
For a given treatment, the probability of survivals is determined by the number and the 
resistance of microorganisms and by the environment (moisture content, thermal 
energy and time for steam sterilization) in which they exist during treatment [45].  
2.4.1 Moist Heat Sterilization 
Moist heat sterilization is the most efficient biological agent greatly used in 
pharmaceutical industry and it is a physical method as radiation and filtration (gaseous 
method is a chemical one) [50]. There exists three forms of moist heat sterilization: 
Autoclaving (dry saturated steam), boiling water/steam at atmospheric pressure and hot 
water below boiling point.  
Autoclaving (Figure 2.11) is the method used to sterilize the CMCA mixture packed in the 
syringes, uses pressurized steam to destroy microorganisms. This is the most effective 
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method for the denaturation of nucleic acids and proteins and it had been 
demonstrated that it is the most hard-hitting for aqueous preparations [46].  
 
 
 Figure 2.11  
An Autoclave [4]. 
 
A generic sterilization cycle includes heating, sterilizing and cooling phases characterized 
by physical parameters such as exposure time, temperature and pressure, governing the 
efficiency of the sterilization. 
The accepted range of sterilizing temperatures is between 118 and 134°C and the US 
Pharmacopeia (USP) explains, in a footnote, that “an autoclave cycle, where specified in 
the compendia for media or reagents, is a period of 15 minutes at 121°C, unless 
otherwise indicated”. Both the European Pharmacopoeia (EP) and the British 
Pharmacopoeia (BP) recommend a heating process at minimum of 121°C for 15 minutes 
as a reference condition for aqueous preparations. 
The exposure timing begins when the temperature sensor (placed in the coldest spot of 
the chamber) reaches the set temperature; the sterilization time can be exceeded to 
guarantee a sterilization, also in a worst case of contamination, if the material is heat-
resistant. On the other side to avoid product’s degradation it is suggested to use a 
longer cycle at lower temperatures [50].  
The cycle presented in Figure 2.12 shows an initial prevacuum cycle ensuring a more 
effective penetration of the saturated steam in the material and avoiding the presence 
of cold spots [50,51]. 
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Figure 2.12 
Sterilization cycle with forced air removal [46]. 
 
The parameters usually used to identify a particular sterilization cycle and considered to 
evaluate the effects it has on the product are the followings: 
 
1. D value (or decimal reduction value) represents the temperature coefficient for 
the lethal process and is the exposure time in minutes required to cause a 1-
logarithm or 90% reduction in the population of a particular microorganism. 
Changing temperature the microorganism’s resistance change. The smaller the D 
value, the more sensitive the organism is to the lethal agent. 
2. Z value: defined as the number of degrees of temperature required for a 1-
logarithm change in the D value. 
3. F0 value, at a particular temperature, other than 121°C, is the time (minutes) 
required to provide the lethality equivalent to which is provided at 121°C for a 
stated time. This value could be used to compare the lethality and the 
aggressiveness of a sterilization cycle. The greater the F0, the greater the 
treatment strength. 
 
                    
Equation 2.7 
Relationship between F0 and the microorganisms inactivation [10] 
. 
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2.4.2 Three Different Sterilization Cycles 
Changing the sterilization cycle parameters, presented in Paragraph 2.4.1, the final 
characteristics, of the sterilized product, are influenced, three different cycles were 
tested in order to choose the one able to guarantee sterility and to maintain a correct 
mechanical behaviour of the product. The following parameters, reported in Table 2.6, 
were used by a subcontractor, to perform the test. 
 
PARAMETER CYCLE 1 CYCLE 2 CYCLE 3 
Exposure Temperature [°C] 121,2 121,2 121,2 
Temp. deviation limit (high) [°C] 1,0 1,0 1,0 
Temp. deviation limit (low) [°C] 1,0 1,0 1,0 
Exposure F0 [min] 15 11 11 
Z value [°C] 14,1 14,1 10,0 
Table 2.6 
Sterilization Cycle’s Specimens 
 
Comparing the three cycles’ parameters it is clear that: 
 
 Exposure Temperature was the same for each cycle 
 Cycles 2 and 3 presented a lower value of F0 that mean that they had less 
exposition time than Cycle 1. 
  Cycle 3 had a lower Z value than Cycles 1 and 2 so, with Cycle 3,  more time was 
required to obtain the same mortality effect on microorganisms (in the same 
time the mortality value was lower [52]). 
 
These considerations allow to affirm that Cycle 3 is the most conservative and Cycle 1 
the most aggressive with respect to mechanical properties. To get evidence of the 
influence of each cycle, in the CMCA mixture, an analysis of the rheometric properties 
has been performed at the Industrial and Information Department of Engineering of the 
University of Trieste. 
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In the mechanical spectrum, reported below, the trends of G’ and G” are indicated for 
each cycle and it can be seen there have been done two measures for each cycle sample 
in order to check reproducibility. 
Considering air filling the three sterilization cycles caused similar degradation in fact the 
G’ and G” values at 0,5Hz and 2,5Hz are similar. If the nitrogen filling is considered, it can 
be seen that Cycle 1 is the most aggressive and caused the major reduction of both 
moduli, while Cycle 3 is the most conservative and presented the biggest values of the 
elastic and the viscous moduli. It is important to consider that the product used in the 
three different cycles came from the same batch and so the initial characteristics were 
the same.  The rheometric data confirmed that air filling is sensitive to all the three 
sterilization cycles considered, while nitrogen resists better to degradation presenting, 
after Cycle 2 and 3, values greater than the values obtained by air filling in Cycle 1, 2 or 
3. 
 
 
Figure 2.13 
Elastic and viscous moduli of CMCA mixture sterilized with the three different cycles (O2 filling). 
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Figure 2.14 
Elastic and viscous moduli of CMCA mixture sterilized with the three different cycles (N2 filling). 
 
2.5 PARAMETERS INFLUENCING CMCA CHARACTERISTICS 
From previous investigations, it becomes clear that every process step may influence  
the final product’s behaviour. Thus, it is necessary to understand which treatments, 
substances, conditions of working and storage, improve or decrease mechanical, 
rheological and chemical characteristics of CMCA gel and polymer. Each parameter was 
considered and analysed to understand how it is related to the product’s characteristics 
and how it can modify them. 
2.5.1 Sterilization Effects 
Sterilization is a mandatory step that the product has to withstand: it has to be 
investigated how it influences viscosity. As described before, autoclaving expose the 
CMCA mixture to high temperature and pressure causing a decrease in viscosity. Under 
normal temperature conditions, the effect is reversible but longer heating and higher 
temperatures degrade CMC and permanently reduce viscosity [53].  
Pei-I Chu et al. [51] demonstrated that the increase of the exposure time, decreases the 
viscosity of the CMC gel (see Table 2.6). 
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Table 2.6 
CMC viscosity with different exposure time [51]. 
 
They also demonstrated that the lower the starting pressure the greater is the final 
viscosity. There is a thermodynamic reason in fact the reaction rate is related to 
pressure p as shown in Equation 2.8. 
 
     
   
 
   
   
 
Equation 2.8 
Starting pressure and viscosity relationship. 
 
where K is the rate constant, p the reaction pressure, V is the volume of the activated 
complex in the solution, T the absolute temperature and R the universal gas constant. 
For a bimolecular reaction, the activated complex is supposed to have smaller volume 
than the sum of the values for the reacting molecules; because of this, increasing the 
pressure, the reaction rate should increase inducing a greater degradation. The starting 
pressure is also directly proportional to oxygen’s concentration. To demonstrate that 
oxygen could cause material’s degradation Pei-I Chu et al. tried to perform some cycles 
of sterilization by autoclave, flushing the product with oxygen, nitrogen or both. What 
become clear was that the presence of oxygen induced a greatest degradation, than the 
presence of nitrogen or both oxygen and nitrogen, with the consequent  highest 
viscosity drop. The presence of the two gasses contemporary, caused an intermediate 
degrading condition between the higest degradation caused by O2 and the lowest 
degradation caused by N2 [51]. 
As demonstrated, the sterilization affects the product’s properties and differences in the 
sterilization cycle differently influence the stability of the product.  A preliminary study, 
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performed at the University of Trieste, of the effects of the three cycles in the trend of 
the product’s elastic and the viscous moduli, at the different solicitation frequencies, 
confirmed that Cycle 1 is the most aggressive and the one which causes, not only the 
greater degradation at the procedure time, but also that induces a greater drop in 
mechanical properties in time (see Figures 2.15 and 2.16). 
 
 
Figure 2.1 
G’ and G” at 0,5Hz changing in a month storage at room temperture  
 
 
Figure 2.16 
G’ and G” at 2,5Hz changing in a month storage at room temperature 
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A more specific study on the stability of the CMCA mixture will be discussed in the next 
chapter in order to understand its degrading kinetic and its shelf life. 
2.5.2 Other Substances and Storing Conditions Effects 
There are some substances that, while added, can modify the final viscosity of the 
product. The order in which solutes are added is important, in fact if CMC is hydrated 
and the solute is then added, it has only a small effect on viscosity. However, if the 
solute is dissolved before CMC addition, it inhibits breaking up of crystalline areas and 
lower viscosities are obtained [53].  
The presence of NaOH influences the substitution degree (DS) of CMC so it affects  the 
average number of hydroxyl group in the cellulose structure which are substituted by 
carboxymethyl or sodium carboxymethyl groups. If the NaOH concentration increases, 
the DS increases causing also a growth in the tensile strength  of CMC films [54].  
Other substances tested for their effect on CMC viscosity are chelators such as EDTA 
(ethylenediaminetetraacetic acid) which is an autoclave stable chelator. Because of its 
stability at high temperature and pressure, EDTA does not lose its chelating action 
during autoclaving, preventing CMC viscosity loss if added before the treatment. The 
capacity to prevent the viscosity drop is due to the fact that chelators sequestrate metal 
ions that would otherwise catalyse the breakdown of the polymer-gel mixture through 
free radical reactions in the high heat and pressure of the autoclave [55].  
Methionine, methionine derivatives and small peptides comprising one or more 
methionine rediues or derivatives could also be added to CMC preparations but only 
after autoclaving because they are not necessarily stable at high temperatures. These 
substances interact with free radicals preventing their degrading action on CMC. 
Peroxides such as H2O2 can adversely impact the viscosity causing degradation due to 
the fact that the C-H bond is vulnerable to radical mediated oxidation. The higher the 
concentration of hydrogen peroxide, the greater the viscosity loss in the CMC 
preparation is. Many anti-oxidants exists but the majority of them cannot withstand the 
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autoclave process. EDTA can be used to prevent oxidative, as well as autoclave, viscosity 
drop. 
An autoclaved CMC preparation stored at 40°C for four weeks or at 5°C for six months in 
absence or in the presence of 400ppm of EDTA, 1,8mg/ml of methionine or both could 
give information on the effects of the substances presented and about their interaction. 
It was seen that, at 40°C without EDTA or methionine, viscosity decreased significantly in 
presence of H2O2 which concentration was of 2, 5, 20 or 50ppm. EDTA can reduce the 
rate of viscosity loss but could not completely prevent it storing at 40°C. Methionine was 
able to prevent the viscosity loss even at the greater concentration of hydrogen 
peroxide and the same result can be consequently obtained in the presence of both 
EDTA and methionine. In case of storage at 5°C, EDTA can itself prevent the viscosity loss 
possibly because at this temperature the rate of generation of free radicals is slower 
allowing EDTA to exert its sequestering activity on catalytic metals minimizing the 
amount of free radicals [55].  
The last consideration underlines the importance of a proper storage in order to 
maintain the desiderated characteristics and to retard aging effects. Considering storage 
conditions the protection from air with an airtight container prevent viscosity drop 
[51,53]. It is important also to protect against microbiological attack, to avoid prolonged 
exposure to elevated temperatures and exclude sunlight [53]. 
 
  
A New Device for Viscosupplementation Treatment: Development of Manufacturing and Control 
Processes 
 
 
49 | 
 
 
CHAPTER 3: STABILITY AND SHELF LIFE 
 
 
 
 
 
 
 
 
 
 
 
3.1 RHEOMETRIC ANALYSIS 
The rheological tests, which provide the values of the elastic and the viscous moduli, 
were carried out at the Department of Industrial Engineering and Information 
Technology of the University of Trieste, using a rotational stress controlled rheometer 
equipped with a parallel plate device. The instrument controls the torque M (related to 
the shear stress) applied to the system, and measures the rotational velocity or angular 
displacement (related to the shear rate or strain, respectively). The ratio between the 
maximum stress and the maximum strain is the dynamic modulus G* that can be split 
into two components: the elastic and the viscous moduli. Ideal elastic fluids present a 
dynamic response to sinusoidal oscillatory shear, in which stress and strain are in phase 
while ideal viscous fluids are in quadrature [58]. For a viscoelastic material stress and 
strain are out of phase of an angle δ between zero and π/2. If tan(δ)<1, the elastic 
behaviour predominates since tan(δ) is the ratio between the viscous modulus G” and 
the elastic modulus G’.  
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Both the stress and strain functions are sinusoidal. The following chart reports the stress 
and strain expressions for an elastic solid, a viscous fluid and a viscoelastic material. 
 
SAMPLE STRAIN STRESS 
Elastic Sample                                
Viscous Sample                                 
Viscoelastic 
Sample 
                        
                          
Table 3.1 
Stress and Strain expressions for elastic, viscous and viscoelastic samples. 
 
G’ and G” values can be derived from the fundamental experimental data, i.e. the 
maximum stress, the maximum strain and the phase shift as follows: 
 
    
  
  
      
Equation 3.1 
Elastic Modulus expression. 
 
    
  
  
      
Equation 3.2 
Viscous Modulus expression. 
 
The mechanical spectrum of a material is composed of two curves, describing the 
dependence of the elastic and the viscous moduli on the imposed oscillation frequency. 
They are obtained with a frequency sweep test (FS) in which frequency is increased or 
decreased within a predetermined range, keeping constant the maximum strain or the 
maximum stress. The experiment is performed in small oscillation amplitude mode 
(SAOS) to obtain information only perturbing the material structure and then 
characterizing its linear viscoelastic properties [58,59]. A schematic representation of 
the frequency sweep test is reported in Figure 3.1. Two consecutive frequency 
conditions are separated by a pause in order to avoid interaction effects. 
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Figure 3.1 
FS Test with decreasing frequency and pauses [58]. 
 
In the case of the CMCA polymer-gel composite, the mechanical spectrum obtained 
from the frequency sweep test allows describing its behaviour in the whole frequency 
window explored and also individuating its viscoelastic responses at 0,5 Hz and 2,5Hz, 
which are the characteristic frequencies of the movement of the knee joint in walking 
and running conditions, respectively [26]. Comparing the mechanical spectra of the CMC 
raw material and the CMCA composite material, that represents the final product, it can 
be evinced how the manufacturing process, in its totality, changes the rheological 
behaviour. Focusing the attention on CMCA mixture, in correspondence of 0,5Hz, G’ is 
between 31,0 and 45,0 Pa (average 38,4 Pa) while G” is in the interval 32,0-41,0 Pa (av. 
37,0 Pa); for 2,5Hz the elastic and the viscous moduli are between 70,0-96,0 Pa (av. 83,0 
Pa) and 75,0-90,0 Pa (av. 82,6 Pa), respectively. These results were obtained in a series 
of experiments performed on different samples of the product.  
Another interesting rheological characterization of the linear viscoelastic properties of 
the material can be obtained from a creep-recovery experiment. The test is carried out 
by applying a constant stress on a material’s sample to obtain the corresponding strain-
time curve. In the following recovery segment the stress is removed and the strain 
relaxation is recorded [59]. The total recoverable deformation is a measure of the 
material elasticity and corresponds to the energy stored in the sample during the creep 
segment, while the non recoverable part refers to the dissipated energy related to the 
sample viscosity [60]. The recovery test is more important: a continuous shear rate 
condition is applied between two oscillatory time sweeps performed at 1 Hz and small 
amplitude oscillatory conditions. The third segment serves to evaluate if and how much 
both the viscoelastic moduli recover their original values, attained in the first oscillatory 
time sweep before the continuous shear segment. 
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The percentage of recovery for both moduli is calculated from the following expressions: 
with Equations 1.1 and 1.2. 
          
       
        
  
Equations 1.1 
G’ percentage variation. 
 
          
       
        
  
Equations 1.2 
G” percentage variation. 
 
Gbefore is the value of the considered modulus (G) attained at the end of the first segment 
before constant shear rate condition, and Gafter is the value at the end of the prolonged 
final segment at 1Hz as shown in Figure 3. 
 
 
Figure 3 
Example of recovery test. 
 
Observing the test conducted on sample of CMCA mixture filled in oxygen or nitrogen 
and sterilized with the three different cycles, described in Chapter 2, it is possible to get 
a further confirmation that the filling technique, based on nitrogen as propellant gas and 
on the sterilization Cycle 3, presents the best recovery characteristic. The recovery test 
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was also carried out applying different shear rate values (100s-1, the most aggressive, 
10s-1 and 1s-1). The greater the shear rate, the lower was the recovery. 
All the test described were performed at controlled temperature of 25,0°C (SD 0,1°C). 
 
3.2 STABILITY AND SHELF LIFE 
In order to get a more specific characterization of the CMCA mixture, it becomes 
necessary to study the stability of the material in different environmental conditions 
with the aim to define the proper storage procedure and to set a correct shelf life for the 
final product. 
Real time studies are the best way to understand the real aging and the degradation of 
products, but it is not always possible to perform them due to the long time they take, 
that are not compatible with commercial requirements. In order to avoid this limit, it is 
possible to perform accelerated tests, in which the material is subjected to an external, 
more severe or more frequent, stress for a relatively short period of time. 
To perform an accelerated aging test, and to understand the correspondence between 
real time aging and accelerated experimental time of the CMCA polymer-gel composite, 
a test has been designed referring to the standard guide ASTM F 1980-07 Standard 
Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices [61]. This 
standard is currently used for all Lima products to test only the resistance and the 
potential degradation of packaging. 
The initial target was to test the packaging resistance through accelerated aging process 
and in the meanwhile understand any eventual modification in chemical-physical 
structure of the product.  
This procedure is based on the assumption that chemical reactions involved in the 
degradation of materials follow the Arrhenius’ reaction rate law: a 10°C increase or 
decrease in temperature of a homogeneous process results respectively in a two times 
or a half time change in the rate of a chemical reaction. 
This concept is expressed by a Q10 aging factor of 2 that is a value suitable for the great 
part of materials for packaging such as TYVEK® or PETG but it was not appropriate to 
perform the test on the CMCA composite material [61]. In fact the accelerated test, 
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carried out according to standard’s specifications, caused a very high degradation of the 
product ; in these conditions, it was not possible to predict any degradation kinetics, 
and, hence, to describe the degradation of the product without completely destroying it, 
another value for the Q10 has to be investigated. The description of the test and the 
results obtained are presented in paragraph 3.2.1 where Figure 3.3 shows the 
differences between the results and the real aging of the product. This figure clarifies 
why a Q10 value of 2 was not appropriate for the product. 
A possible  reason why mechanical properties vary in time is that polymers are degraded 
by random scission of the bonds, causing a reduction in chains length and consequently 
a viscosity drop. The relationship between viscosity and molecular weight is expressed 
by the Mark-Houwink-Sakurada equation [62,63]: 
 
η=K*Ma 
Equation 3.3 
Mark-Houwink-Sakurada equation [62]. 
 
K is a constant and a is a scalar which relates to the stiffness of the polymer’s chains. 
These values are typical of the polymer analysed and they have been determined also 
for CMC (carboxymethyl cellulose) by Wirick M. G. in 1968 [62]. 
The relationship between degradation and mechanical changes in a product is widely 
represented in literature: for example in “Additives to Lower and Stabilize the Viscosity 
of Pyrolysis Oils during Storage” by Diebold et al. [64] they demonstrated that pyrolysis 
oils contain reactive organics compounds that, during storage, interact changing physical 
properties as viscosity (in this particular example it increased in time). Due to the fact 
that this process progressed in time, they used it as a tool to obtain an aging measure; in 
fact they asserted that viscosity measurements are an indirect measure of the 
polymerization reactions that occur in the oil and the best way to measure it in polymers 
field [64]. 
In 2010 it was reported [65], as a good procedure to determine the stability of the 
analysed product with accelerated aging technique, the measures of viscosity before and 
after the test to determine its change that is related to the polymerisation reaction. 
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They also argued that a small change in viscosity corresponds to a more stable material, 
confirming that the material’s stability is strictly related to the physical and mechanical 
stability in time. 
Another reason why viscosity is a measure of the reaction rates is that viscosity is 
connected with diffusion coefficients of the molecules in mixtures [66,67]. This is 
because viscosity changes in time, and thus mechanical properties changes, are 
therefore in relation with the rate constant of the reaction [68].  
The exposition to high temperature and the monitoring of consequent mechanical 
changes is presented as a good testing procedure in “Accelerated Testing, Statistical 
Models, Test Plans and Data Analyses” [69] corroborating the choice to perform an 
accelerated test exposing the CMCA polymer-gel to high temperature and to evaluate 
the corresponding drop in the elastic and viscous moduli by rheometric analysis. 
FDA Guidance for Stability Testing [63] recommends to perform physical, chemical, 
biological and microbiological test before and after an aging procedure, both real time 
and accelerated, to be able to quantify the aging effects. 
Considering these studies and results collected from different polymeric products and 
applications, it can be assumed that mechanical properties investigation may be a 
suitable way to get information on the rate of aging of the CMCA polymer-gel composite 
material. However, in this particular case, viscosity is not a suitable parameter for 
material characterization, due to the biphasic polymer and gel structure and the related 
viscoelastic behaviour.  
In the previous Chapter, G’ and G’’ have been widely used for the characterization of 
CMCA blends, so that it can be assumed that any variation of these moduli vs. time at 
different temperatures may represent a proper method to evaluate material 
degradation. 
These parameters are connected with mechanical behaviour change; chemical changes, 
as for example pH variations, could be taken as a measure of the product aging [62] but 
it has been seen that the CMCA composite material does not show any changes of this 
characteristic. 
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It has to be considered that G’ and G” are frequency-dependents and a reference 
condition has to be taken into consideration: assuming 0,5 Hz and 2,5 Hz as reference 
frequencies, it could give the information on the field of application for the considered 
medical device. It is clear that the most suitable way to analyse the aging of the CMCA 
composite material is to consider the elastic and the viscous moduli and their changes to 
investigate the aging of both the polymeric and gel components. A measure of the rate 
of the elastic and viscous moduli drop is an indirect measure of the degradation process 
so it allows performing aging studies in order to understand the degradation kinetics. 
Another assumption must be done before proceeding with testing: the model 
considered has been set considering that the degradation follows the Arrhenius’ 
reaction rate function. This means that a 10°C increase or decrease in temperature of a 
homogeneous process results respectively in a two times or a half time change in the 
rate of a chemical reaction.  
3.2.1 Q10 and Accelerated Test  
To perform accelerated test and to find out the correspondence between real time and 
accelerated aging, the relationship presented in Equation 3.4 is necessary. Desired (RT) is 
the real time aging corresponding to the accelerated aging obtained exposing to high 
temperature the sample for the Accelerated Aging Time (AAT). 
 
    
           
   
 
Equation 3.4 
Accelerated Aging Time [61]. 
 
AAF is the Accelerated Aging Factor that can be found with the relationship existing 
between the material’s Q10 and the difference between the room temperature and the 
high temperature considered, as shown by the Equation 3.5. The Q10 value is a 
parameter connected with a change in the degradation reaction rate at two 
temperatures which differs for 10°C as Expression 3.6 will show. 
 
 
A New Device for Viscosupplementation Treatment: Development of Manufacturing and Control 
Processes 
 
 
57 | 
 
       
 
       
    
Equation 3.5 
Accelerated Aging Factor [61]. 
 
TAA is the accelerated aging temperature [°C] and TRT is the room temperature [°C]. 
For example, if the aim is to age the product of one year exposing it at a temperature of 
55°C instead of waiting a year at room temperature, the procedure, considering the 
standard value for the Q10, is: 
 
       
       
         
and  
    
   
   
       
 
To obtain a one-year-aged product exposing it to 55°C the treatment has to last 38 days. 
Considering the degradation reaction for the CMCA composite material, preliminary 
experimental data, whose results are presented in Figure 3.3, suggested a value higher 
than two for the Q10 parameter. The test was performed on product’s samples filled 
with nitrogen in glass syringes. It was used a Q10=2 and exposure temperature of 55°C 
for 10 days, corresponding to 90 days at 22,5°C. The viscosity loss was of about 76,57% 
that was not corroborated by real time aging observed in 90 days in the sample analysed 
in which the viscosity loss was about 44,75% as Figure 3.3 illustrates. The difference 
between the sample treated with accelerated aging and the one naturally aged was so 
great that was appreciable at sight. The values of viscosities were calculated with a 
vibrational viscometer at the frequency of 30Hz.  
Assuming for example a Q10 of 2,6 the test time will correspond to 223 days giving 
evidence that a greater aging factor means that the exposition time is equivalent to a 
longer real time aging. 
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Figure 3.3 
Comparison between30 days aging in Real Aging and Accelerated Aging with Q10=2. 
 
In order to find out an evidence of this hypothesis, it becomes necessary to test the 
material at different temperatures and to define the correct Q10 value able, with an 
additional test, to simulate the aging for the desiderated period and to evaluate the 
mechanical characteristics. 
The Q10 value is connected with a change in the degradation reaction rate at two 
temperatures, which differs for 10°C, as the following expression shows. 
 
     
   
   
 
  
       
 
Equation 3.6 
Q10 expression. 
 
KT1 and KT2 are the reaction rates at the two temperatures T1 and T2. Because of the 
difficulty to give a precise and correct value at the degradation reaction rate, it was 
developed a different procedure to evaluate the Q10. 
Starting from available data of real time aging in one and two months (values were 
collected at time zero at the beginning of the experiment, after one month and after 
two months), coming from the evaluation of the differences in the rheological properties 
it was hypothesized the worst case aging trend for the elastic and the viscous moduli 
characterized by a linear drop of their values.  
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Although it is known that degradation kinetics usually follow a parabolic trend, in this 
case the linear model has been preferred for two main reasons:  
 
 during the first months the linear and parabolic trend are almost overlapping; 
 the linear model represents the worst case hence the most conservative 
approach to set a preliminary shelf life. 
 
The real trend and the one supposed for the study are presented in the following 
picture. 
 
 
Figure 3.4 
Real trend (violet) and the hypothesized trend(light green). 
 
The real trend, in violet in Figure 3.4, is characterized by an initial high degradation 
followed by a period in which the rate of degradation becomes relatively constant and 
remains constant for a considerable time [67]. The hypothesized trend (light green) 
represents the worst case, in fact it supposed that the high degradation still remain 
through the whole life of the product analysed. In the previous picture, the period of 
time corresponding to two months is represented due to the fact that the hypothesized 
trend was developed by the use of the data coming from the real time aging in two 
months. 
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Three glass syringes, filled in nitrogen, were used to evaluate a greater aging by 
accelerated test. The first syringes were analysed by rheometric analysis (FS test) 
contemporary to the start of the exposition to high temperature (40°C and 50°C, 
respectively) of the other two syringes. The high temperature test lasted eight days and, 
at the end, the syringes were undergone to the frequency sweep test and the values of 
G’ and G” were collected. 
The temperature range chosen was not very large but there is no evidence that Q10 has a 
constant value for all the temperatures [71] and in the intended use of the product it 
will not be exposed to higher temperatures.  
The percentage of the remaining Elastic and Viscous Moduli, after one and two months 
storage at 22,5°C, were calculated at three frequencies: 0,5 Hz and 2,5 Hz in accord with 
the walking and running condition respectively and 1,47 Hz to simulate an intermediate 
situation. These values are reported in Table 3.2.  
The first values, at time zero for the test, was taken after one month from the product’s 
production and G’ (82,99Pa at 2,5 Hz) and G”(82,55Pa at 2,5 Hz) are very similar to the 
values for the human synovial fluid in the knee (at 2,5 Hz: G’=117 ±13 and G”=45 ±8) 
[72]. 
 
SAMPLE 
G’0,5 
[%] 
G”0,5 
[%] 
G’1,47 
[%] 
G”1,47 
[%] 
G’2,5 
[%] 
G”2,5 
[%] 
1month at 22,5°C storing 97,63 92,29 94,25 92,35 92,10 91,13 
2months at 22,5°C storing 83,45 83,09 79,71 83,62 80,08 86,06 
Table 3.2 
Percentage Remaining of G’ and G’ after one or two months storage at 22,5°C 
 at 0,5 Hz, 1,47 Hz and 2,5 Hz. 
 
These remaining percentages of both moduli were compared to the predicted ones with 
the linear drop hypothesized and, in this way, the correspondence between 8 days aging 
at high temperature (40°C and 50°C), and the days in real time aging was found out, as 
Figure 3.5 illustrates. 
Eight days at 40°C caused a modulus loss (both for G’ and G”) of about 30-40% 
corresponding to 130 days at room temperature in accord with the linear prediction 
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(green line of Figure 3.4); 8 days at 50°C caused a G’ and G” loss of about 40-50% as 160 
days at 22,5°C. 
This relationship between the number of days at high temperature and number of days 
at room temperature allowed finding out the value of the Q10, by the use of Expressions 
3.4 and 3.5 which were calculated separately for the three frequencies and for G’ and 
G”. 
 
 
Figure 3.5 
Correspondence between degradation caused by real time and accelerated aging. 
 
No great differences were observed between the two moduli nor among the three 
frequencies considered; comparing the Q10, obtained by the use of the data coming from 
the experiment conducted at 40°C or 50°C, they were not the same as it can be seen in 
the next chart. The average value of Q10 calculated for the experiment at 40°C was 4,9 
and the average value for the test at 50°C was 3,06. A lower Q10 value means that the 
same accelerated test corresponds to less days of real aging: this outcome induces 
thinking that the product ages faster. 
This very marked situation at 50°C can be easily explained considering how the aging 
model was created: a lower temperature (40°C) induces a lower aging and the lower the 
aging the lower is the difference between the real drop in the moduli and the predicted 
linear drop (as the Figure 3.6 illustrates). 
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Q10 G’0,5 G”0,5 G’1,47 G”1,47 G’2,5 G”2,5 
40°C test 5,52 4,9 4,9 4,68 4,9 4,9 
50°C test 3,23 3,03 3,03 3,03 3,03 3,03 
Table 3.3 
Q10 value calculated for each one of the three frequency analyzed, both for G’ and G”. 
 
In the following picture it is possible to see two yellow areas representing the difference 
existing between the real aging (violet) and the hypothesized drop used for the study 
(light green). The areas corresponding to a remaining percentage of about 50%-60% is 
bigger than the one corresponding to 60%-70% giving evidence that the experiment 
conducted at 50°C, due to the greater degradation it induces, produces a higher aging 
and a higher gap from the real aging model. This is the reason why the Q10 value 
obtained from the experiment at 40°C was chosen as more representative of the real 
aging and anyway it still represent a worse case. 
 
 
Figure 3.6 
Real trend (violet) and the hypothesized one (light green) with the correspondence between 
aging days and the drop in the values of G’ and G”. 
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When a Q10 value is defined, it is possible to develop an aging experiment, exposing the 
product to high temperature for a precise testing time to obtain a product aged as 
desired.  
The test shows that the Arrhenius model was not totally suitable for the CMCA polymer-
gel because an increase or decrease in temperature does not result in a two times or a 
half time change in the rate of the degrading reaction, respectively. Further 
investigations should be done to verify the results obtained in more samples.         
3.2.2 Storage Conditions 
Storage conditions are fundamental to preserve product’s characteristics and to prevent 
fast degradation. The adoption of glass syringes and of the automatic filling technique 
using the inert gas nitrogen was justified by better storage condition as illustrated in 
Chapter 3. In addition to these choices, the storage at 4°C was compared to the storage 
at 22°C to verify if a lower temperature could reduce the aging process extending the 
CMCA polymer-gel shelf life. 
The effects on product’s characteristics were analysed by rheometric analysis and the 
comparison between the elastic and viscous moduli in the two products, after two or 
three months of storage was performed. 
The comparison between the remaining percentage of G’ and G” after one or two 
months of storage at room temperature or three months at 4°C are presented in Table 
3.4. 
 
SAMPLE 
G’0,5 
[%] 
G”0,5 
[%] 
G’1,47 
[%] 
G”1,47 
[%] 
G’2,5 
[%] 
G”2,5 
[%] 
3months storage at 4°C 89,10 95,07 87,75 92,38 88,69 89,39 
1month storage at 22,5°C 92,10 91,13 94,25 92,35 97,63 92,29 
2months storage at 22,5°C 83,45 83,09 79,71 83,62 80,08 86,06 
 
Table 3.4 
G’ and G” remaining percentage after storage at 4°C or 22,5°C  
at 0,5 Hz, 1,47 Hz and 2,5 Hz. 
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The table above shows that storage of the product al 4°C reduces the degradation rate 
and the drop of both moduli. This is the reason why it was chosen, as the best condition 
for the CMCA polymer-gel composite, allowing the extension of the shelf life. 
It is known that the Q10 value is constant for a small temperature interval but if other 
processes are initiated in the material, they can change the reaction rate and thus the 
aging rate [71]. The evidence is given by Equations 3.6 and 3.7 from which it is clear that 
a Q10 = 4,97 is not adapt to represent the situation characterised by the aging at 4°C and 
the accelerated aging (accelerated with respect to 4°C) at 22,5°C. Applying them, it 
resulted that 90 days at 4°C will correspond to 4,63 days at room temperature that is 
very different from the real situation: in fact from the chart above, it can be seen that 90 
days at 4°C induced a degradation similar to the one reached after 30 days at 22,5°C. 
The Q10 value, calculated imposing this correspondence, with the equations mentioned 
above, results in 1,81. 
This value means that 60 days at 22,5°C correspond to 180days at 4°C: if the product is 
stored in fridge, after six months it will present about the 80% of the initial values of G’ 
and G” giving evidence of a good stability over time. 
In conclusion, this test highlighted that it is preferable to store the product at 4°C than at 
room temperature and it also allowed stating the good resistance over time of the 
rheological properties of the product. 
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CHAPTER 4: PROJECT MANAGEMENT AND  
MECHANICAL TESTS 
 
 
 
 
 
 
 
 
 
 
 
The three mechanical tests performed to evaluate the wear of prosthetic implants in 
presence of CMCA polymer-gel dispersions, described in this chapter, are characterised 
by a great number of subsequent, and strictly interconnected, phases. This is the reason 
why a delay in one of them can prolong the whole process. The last steps, consisting in 
the tests themselves, were long way off the time in which they were planned.  
Because of these facts, it was decided to approach the tests with the aid of project 
management to be able to organise activities and to estimate the time required, also in 
case of unexpected events. 
4.1 PROJECT MANAGEMENT OF THE MECHANICAL TESTS 
Project management is the discipline of planning, organizing, securing and managing 
resources to achieve specific goals as projects, which are temporary attempt with 
defined beginnings and ends [74].  
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Project management has evolved from a management philosophy, restricted to a few 
functional areas, into a business process. Its extension to all disciplines started with 
engineering but now project management resides in every profession including 
information systems, health care, consulting, pharmaceutical, banks and government 
agencies [75]. 
By the 1990s many companies begun to realize that implementing project management 
was necessary due to some driving forces as competitiveness, new project development, 
efficiency and effectiveness. For example, if multiple simultaneous and/or large capital 
projects are daily present in a company, it will become important to drive to project 
management in order to manage them in the most efficient way. Instead, considering an 
organisation that heavily invests in R&D activities, the management activity is useful not 
only to organize the activity, but also to analyse each project and to understand if it is 
working good or if it is necessary to stop it. 
Five project management methodologies exist [75] and are listed below: 
 
1. Project Management defined as the basic principles of planning, scheduling and 
controlling work. 
2. Total Quality Management which is the process aiming at assuring that the final 
product or the end result will meet the quality expectation of the customer. 
3. Concurrent Engineering that is performing a work in parallel rather than in series 
in order to compress the project plan without incurring serious risks. 
4. Risk Management which corresponds to the process of identifying, quantifying 
and responding to the risks of the project without any material impact on the 
project’s objectives. 
 
Only one criterion is usually chosen to get best results in the organisation of every 
activity, but it is also possible to integrate all of them into a single process as Figure 4.1 
shows. 
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Figure 4.1 
PM methodologies [75]. 
 
The mechanical tests, described in paragraphs 4.2 and 4.3, were organized and planned 
with the help of Project Management to have a complete view of all the necessary steps 
and their interaction. The entire organization was carried on with the help of a planning 
software as Figure 4.2 shows. 
The following scheme reports all the process phases, the time they required and their 
interactions giving an idea of the time necessary to complete the tests.  
 
 
Figure 4.2 
Activities Planning for Mechanical Tests. 
 
The scheme obtained was useful to organize all the activities, prepare machines and the 
necessary material, and to plan the tests that have been conducted by subcontractors 
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like the ions test. All of these activities gave the possibility to predict the consequences 
of an unexpected event in terms of late. In this way it was possible to plan the work 
considering any adverse events giving the possibility to afford them. 
4.2 KNEE JOINT SIMULATOR 
This test consisted in the analysis of the wear behaviour of total knee prostheses in the 
presence of diluted CMCA composite material, compared to diluted calf serum as 
lubricants. 
The second lubricant medium was composed of a solution of BCS (bovine calf serum)  
diluted at 25% W/W in deionized water with the addition of EDTA (7,5 g/l), to bind 
calcium phosphate, and Sodium Azide (4 g/l) to retard bacteria-induced degradation. 
This composite fluid will be termed in the following test as “serum” to mean all its 
compounds with the specified concentrations. The BCS has itself a total protein content 
of 72 g/l and this is why it has to be diluted to reach the concentration of 18 g/l in accord 
with the international standard [76,77]. Serum has been demonstrated to have the 
capacity to recreate “physiological wear-rates” in a manner that neither water nor saline 
solutions had achieved [78]. 
In order to define the worst case, and reduce performances, the CMCA polymer-gel was 
diluted at 75% W/W ratio between the composite material and the calf serum. This 
operation reduced the mechanical properties of the fluid in which the prostheses were 
immersed. The CMCA mixture dilution was performed in order both to simulate the 
worst case for the product and the situation in which the product is injected in a joint 
containing synovial fluid. It is also possible that the product will be injected in a knee 
that has afforded arthrocentesis which are knees not containing synovial fluid; in this 
case the product will not be subjected to dilution.  
The machine employed is a servo hydraulic four station knee joint simulator with a 
testing frequency of 1 Hz (admitted SD: 0,1 Hz [76]) able to reproduce a cyclic variation 
of flexion/extension angle and contact force to the interface between tibial and femoral 
components, simulating normal human walking. The specimens, used to create the 
correct movement, are defined in the International Standard ISO 14243-1 [76]. 
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Figure 4.3 
Applied Forces on the Knee Prosthesis [76]. 
 
The applied forces are the flexion of the femoral component (number 1 in Figure 4.3), 
the tibial rotation torque (number 2), the anterior-posterior (AP) force on the tibial 
component (number 3) and the axial force (number 4). 
The knee prosthesis used is composed of three components: the femoral component 
made of CoCrMo, the tibial plate in Ti6Al4V and the liner in UHMWPE (ultra-high-
molecular-weight-polyethylene). Before use, all components were sterilized (the femoral 
component and the liner by EtO, and the tibial plate by Beta Ray). The prosthesis type 
used in this test is presented in Figure 4.4. 
 
 
Figure 4.4 
The knee prosthesis involved in the test 
 
The cyclic variation of forces and angles are reported in Figure 4.5 simulating the typical 
normal human walking cycle. The instrument used is provided of load cells able to verify 
the correct loading of the prosthetic components in accord to the defined load cycle 
selected.  
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Figure 4.5 
Variation during percentage of cycle time of the flexion angle (top left),  
axial force (top right), AP force (bottom left) and rotation torque (bottom right) [76]. 
 
In the test, two workspaces under load were used: one with the prosthesis immersed in 
serum and one immersed in bovine calf serum and CMCA composite material. In 
addition, two other unloaded workspaces (soak control), with the same fluids, were 
used to evaluate material absorption. The soak controls were made of only the liner in 
UHMWPE, which absorbs fluid during the test (Figure 4.6). The absorption measure is 
necessary to calculate the correct value of the wear of the prosthesis, at the end of the 
test: in fact liners lose material but they also absorb fluid. In order to be able to carry on 
this control, these components had to be weighted before and after the test. 
The test consisted of 1x106 cycles of movement during which evaporated fluid had to be 
replaced with deionized water. The level sensor provided a security control: in fact if the 
level of the fluid goes under the limit defined, the machine stops. 
To avoid excessive evaporation the containers have to be closed, as it can be seen in 
Figures 4.6 and 4.7. 
Another control was given by the temperature sensor that had to verify temperature to 
be about 37°C, to reproduce a controlled environment simulating physiological 
conditions (admitted SD: 2°C) [76]. 
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Figure 4.6 
S1 is the soaking sample with serum and CMCA composite; 
S2 is the soaking sample with serum only. 
 
Figure 4.7 shows the knee joint simulator with all the four stations occupied; in the 
analysis performed, only the central positions were used for the test, while the laterals 
were filled with water due to the fact that the machine needs to have all the stations 
occupied: even if the flexion and the rotation could be stopped in the first on the left 
(see Figure 4.7), the axial force could not and in the last position, on the right, the 
movement is simultaneous with the centrals. 
 
 
Figure 4.7 
The knee joint simulator. 
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The test have been stopped after 1 million cycles: then the specimens were removed, 
cleaned and weighted to determine the mass loss (Table 4.1). 
The following chart reports the average weights of the liners in UHMWPE, before and 
after the test, obtained from a set of three measures. 
 
 
SAMPLE 
WEIGHT before 
test [g] 
WEIGHT after 
test [g] 
ABSORPTION 
[g] 
WEAR 
[g] 
Soaking Serum 26,211 26,212 -0,001 - 
Loaded Serum 26,195 26,186 0,009 0,010 
Soaking CMCA-BCS 26,101 26,102 -0,001 - 
Loaded CMCA-BCS 25,914 25,912 0,002 0,003 
Table 4.1 
Absorption and Wear of the UHMWPE liners used in the test. 
 
Wear and absorption values presented in Table 4.1 are represented in Figure 4.8. 
Absorption is defined as the initial weight of the soaking subtracted of its final weight; 
wear is the difference between the absorption of the loaded sample and the absorption 
of the co respective soaking as illustrated by the following equations. 
 
                               
Equation 4.1 
Absorption for the loaded or soaking liners 
 
                                        
Equations 4.2 
Wear of the loaded liners 
 
Wi represents the initial weight, before starting the test, and Wf is the final weight. In 
accord with these conventions, absorption and wear of the loaded liners are positive 
while the absorption of the soaking liners is negative. 
The graph below shows that the presence of a more viscous fluid prevents the wear of 
the UHMWPE liner reducing material loss and its damaging; the wear rate for the 
UHMWPE, immersed in serum, was of 10,2 mg per million cycles while for the same 
component, immersed in the composite material and BCS, it was 3 mg per million cycles. 
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What emerges is that the solution composed of BCS and CMCA polymer-gel reduces the 
wear to one third providing a very effective lubrication. 
 
Figure 4.8 
Knee Wear Test. On the left the results of the liner immersed in serum;  
on the right the results for the liner immersed in CMCA and BCS. 
 
The differences in the surface of the two liners tested under load, was visible at sight. 
The one that was immersed in serum presented a greater damaged area and the 
surface was much more irregular.  
These effects could be better appreciated with the picture enlargements hereinafter 
presented (Figure 4.9). On the right there is the liner tested in serum with the visible 
damaged area and a great presence of scratches; on the left there is the liner tested in 
CMCA composite material and BCS. 
The test gave experimental support to the fact that the product, with its viscoelastic 
behaviour, is able to lubricate and protect surfaces, even under physiological loads, and 
maintain its action over time (1 million cycle were tested). 
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a.   d.  
b.   e.  
c.   f.  
Figure 4.9 
Enlarged photos of the liners used in the knee wear test: 
a-b-c : Liner used in presence of CMCA-BCS; 
d-e-f : Liner used in presence of BCS only. 
4.3 HIP JOINT SIMULATOR 
Metal on metal (MoM) total hip prostheses encountered a great use, mostly in the past, 
and in particular in patients younger than 65 [79], due to the thought that these type of 
prostheses had a great resistance to wear and corrosion; according to that belief they 
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were also known as hard on hard prostheses [80]. The use of hard materials, that have 
been shown to have lower wear rates than metal-UHMWPE couples, took place with 
the aim to extend component life [81]. The great majority of MoM prostheses are made 
of CoCrMo alloys, extensively used for joint replacement due to their wear and 
corrosion resistance; this fact is due to a protective Cr oxide film formed on the surface 
that reduces corrosion and hinder metal ion release [82]. It has to be considered, in 
fact, that loads and articulations could increase corrosion rate and metal ions release.  
 
 
Figure 4.10 
A detail of Metal on Metal coupling tested. 
 
The reason why the production of wear particles was greatly investigated is that adverse 
tissue reactions are believed to be an important factor in the development of osteolysis 
[83]. There is an increasing number of reports of local tissue response mediated by 
degradation products, such as metal ions (usually most of them are Co ions) and wear 
debris, generated by wear and corrosion of Metal on Metal total hip replacements. 
These degradation products can cause hypersensitivity, toxicological risk and local bone 
resorption [82]. It has been demonstrated that MoM implants produce a huge number 
of wear particles in nanometre size, very easily absorbed by the peri-implant tissue and 
disseminated to other organs, which could be found in serum, urine and blood of 
patients with this kind of prostheses [84]. 
The test on the hip simulator (see Figure 4.11) was performed in order to evaluate the 
effects of physiological movements on Metal on Metal total hip prostheses considering 
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wear and ions release. In this test two lubricating fluids were compared: bovine calf 
serum and CMCA mixture. The two testing fluids presented the same concentrations and 
the same additives used in the test performed for the knee prostheses.  
This test was also performed to consider the possibility to use the CMCA polymer-gel 
solution to reduce side-effects in patients with MoM prosthesis and to retard the 
revision operation. To simulate this situation, and generally to represent the worst case, 
the prostheses were previously used for about 5 million cycles (a detail of the MoM 
prosthesis used is presented in Figure 4.10).  
 
 
Figure 4.11 
The four stations (from left to right 8-9-10-11) of the  machine involved in the test. 
 
The testing machine works at 1 Hz (SD 0,1 Hz), in accord with the International Standard 
ISO 14242-3 [85], and the movements it reproduces are the ones hereinafter listed. 
 
 Abduction/Adduction: motion along an axis arranged in the anterior-posterior 
direction through the hip joint. 
 Flexion/Extension: motion that occurs about a transverse axis through the hip 
joint. 
 Inward/Outward Rotation. 
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Figures 4.12 shows the movement described and the force applied by the apparatus to 
test the prostheses which were immersed in the lubricating media.  
 
 
Figure 4.12 
At the top: Abduction/Adduction (1) and Extension/Flexion (2) angles changes during a working 
cycle [4]; at the bottom: Applied force on the loading axis during a working cycle [85,86]. 
4.3.1 Metal Ions Analysis 
Samples of the testing fluid were taken at 250.000, 650.000, 950.000 cycles, in order to 
quantify the presence of metal ions. The volume taken was substituted with the same 
testing fluid, to not influence the test. 
The metal analysis was centred on searching Co, Cr, Mo ions and the investigation on 
the differences between the two testing fluids. The test was carried on by an external 
laboratory and the results are presented in the chart below, with the respective 
standard deviation in brackets. The ion dosage has been performed by ICP (Inductively 
Coupled Plasma); this technique is characterized by a constant CV of 0,2. This is the 
reason why the greater the ion concentration, the greater the standard deviation is. 
 
SAMPLE 
Co250 
[ppm]  
Cr250 
[ppm] 
Mo250 
[ppm] 
Co650 
[ppm] 
Cr650 
[ppm] 
Mo650 
[ppm] 
Co950 
[ppm] 
Cr950 
[ppm] 
Mo950 
[ppm] 
CMCA-BCS 
8 
3,51 
(0,71) 
1,79 
(0,45) 
1,59 
(0,33) 
109 
(21) 
43 
(11) 
8,2 
(1,7) 
128 
(23) 
49 
(12) 
10,6 
(2,2) 
CMCA-BCS 
9 
77 
(16) 
30,4 
(7,6) 
6,2 
(1,3) 
114 
(22) 
43 
(11) 
8,7 
(1,8) 
118 
(22) 
45 
(11) 
9,9 
(2,1) 
Serum  
10 
2,98 
(0,6) 
1,47 
(0,37) 
0,259 
(0,062) 
5,4 
(1,1) 
1,55 
(0,39) 
0,387 
(0,087) 
6,5 
(1,3) 
3 
(0,75) 
0,63 
(0,13) 
Serum 
 11 
109 
(21) 
42 
(10) 
8,6 
(1,8) 
410 
(60) 
156 
(39) 
31,4 
(6,5) 
488 
(71) 
180 
(45) 
39,9 
(8,3) 
Table 4.2 
Metal Ions Concentrations in testing fluids at a different cycles.  
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These values are also presented in Figure 4.13 where a., b. and c. represent the three 
sampling performed. It can be seen that at 250.000 cycles station 8 presents lower ion 
delivery than station 9 although they were both immersed in the same testing fluid. This 
difference disappeared in samples taken at 650.000 and 950.000, presenting a 
comparable level of Co, Cr and Mo. Station 10 and 11, both immersed in serum, 
presented very different levels of ions concentration and in particular station 10 
presented the lowest values at all. This fact can be explained considering that station 10 
was equipped with a prosthesis presenting the best initial condition because it was the 
one which was less damaged by the previous usage. The other three stations were 
characterised by the presence of prostheses with similar initial conditions and, 
comparing them, it can be seen that stations immersed in CMCA polymer-gel and BCS 
(stations 8 and 9) presented lower ions release than the station immersed in BCS and 
deionized water (station 11). These considerations are supported by the results on the 
wear of the metal liners and heads which are presented in paragraph 4.3.2. 
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c.  
Figure 4.13 
Metal ions concentrations in samples of testing fluid taken from the four stations(P8, P9, P10, 
P11) at 250.000 cycles (a.), 650.000 cycles (b.) and 950.000 cycles (c.) 
4.3.2 Wear Analysis 
The wear test, with MoM prostheses, did not need the soaking to be performed, due to 
the fact that metal, unlike UHMWPE, does not absorb the lubricating medium. Liners 
and heads were weighted before and after the test to evaluate their weight loss, caused 
by wear. Table 4.3 reports the weigh at the beginning, at the end and their difference for 
the prosthetic components used in the hip joint simulator. 
 
SAMPLE 
WEIGHT  
before test 
[g] 
WEIGHT  
after test [g] 
WEAR 
[g] 
CMCA-BCS station 8-head 158,135 158,107 0,028 
CMCA-BCS station 8-liner 126,519 126,433 0,086 
CMCA-BCS station 9-head 158,039 158,016 0,023 
CMCA-BCS station 9-liner 128,050 127,988 0,062 
Serum station 10-head 158,234 158,232 0,002 
Serum station 10-liner 128,032 128,027 0,005 
Serum station 11-head 157,460 157,100 0,360 
Serum station 11-liner 127,610 127,448 0,162 
Table 4.3 
Wear of the CoCrMo  liners and heads used in the test. 
 
The results in Table 4.3 are better comparable if represented in graphs as shown in 
Figure 4.12. 
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Figure 4.12 
Wear of the Liners (at the top) and Heads (at the bottom) in CoCrMo for stations 8, 9, 10, 11 
 
Station 10, which was lubricated in serum (BCS and deionized water), presented lower 
wear in accord with the results obtained from the metal ions analysis. 
The three other stations can be better compared due to similar stating conditions; they 
shown that the lubrication with CMCA composite and BCS induced a lower wear, both 
considering liners and heads in CoCrMo. This result is the same that was obtained with 
the ions analysis showing that ions release and wear are connected; the reason is that 
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the wear, caused by the reciprocal sliding of bearing surfaces, generates particles 
removal and metal ions release. 
The same conclusions can be obtained by the analyses of bearing surfaces. The following 
pictures present an enlargement of the CoCrMo heads and liners, used in the test, from 
which it is possible to see that station 11 (named d. in Figures 4.13) is the most 
damaged, station 10 (named c.) the less damaged, while stations 8 and 9 (named a. and 
b. respectively) present an intermediate level of damage because of the protection 
provided by the viscoelastic lubricant media in which they were immersed. 
These considerations agree with the test results presented before, confirming what has 
been obtained with the metal ions analysis. 
 
a.   b.  
c.   d.  
e.    f.  
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g.   h.  
Figure 4.13 
Enlarged photos of CoCrMo prosthetic heads (from a to d) and liners (from e to h) 
a. Station 8 (CMCA composite and BCS), b. Station 9 (CMCA composite and BCS), c. Station 10 
(BCS and deionized water), d. Station 11 (BCS and deionized water), e. Station 8 (CMCA 
composite and BCS), f. Station 9 (CMCA composite and BCS), g. Station 10 (BCS and deionized 
water), h. Station 11 (BCS and deionized water) 
 
4.4 METAL ON UHMWPE HIP PROSTHESES 
CoCrMo heads with UHMWPE liners were used to perform a wear test, on the same hip 
joint simulator described in paragraph 4.3, and to compare the lubrication provided by 
CMCA polymer-gel also with this prosthetic type.  
Three stations (4, 5 and 6) under physiological load were prepared, while station 7 was 
used to perform the soak control. All the four stations were immersed in CMCA 
composite material diluted with BCS at 75% W/W.  
The results upon the absorption and the wear of the same prosthetic components, in 
identical testing conditions except for the lubricating fluid, were given by an external 
laboratory. They tested four prostheses (three under load and one soaking) in BCS 
diluted in deionized water to simulate physiological wear behaviour and, considering the 
UHMWPE liners, they obtained 0,036 g (SD ±0,004) of average wear and an average fluid 
absorption of -0,003 g. 
Before starting the test in CMCA composite, all the components were weighted and the 
same control was performed after 1 million cycles, at the end of the test. The following 
chart presents the wear for all the heads and liners and the absorption only for the 
UHMWPE components. 
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SAMPLE 
ABSORPTION 
[g] 
WEAR 
[g] 
CMCA-BCS station 4-head 0,012 0,012 
CMCA-BCS station 4-liner 0,003 0,005 
CMCA-BCS station 5-head 0,001 0,001 
CMCA-BCS station 5-liner 0,004 0,006 
CMCA-BCS station 6-head 0,001 0,001 
CMCA-BCS station 6-liner 0,003 0,005 
CMCA-BCS station 7-head -0,000 - 
CMCA-BCS station 7-liner -0,002 - 
Table 4.4 
Wear and Absorption for the metal on UHMWPE prostheses 
 
Wear and absorption presented in Table 4.4, are calculated in accord with Equations 4.1 
and 4.2.  
Comparing to the results obtained from the test on serum, it is possible to state that a 
viscoelastic lubricating fluid, such as CMCA polymer-gel composite material, reduces 
wear; in fact, the wear rate of the liners immersed in BCS and deionized water was 35,56 
mg per million cycles (SD 3,79 mg) while the one for liners immersed in diluted CMCA 
composite was 4,92 mg per million cycles (SD 0,14 mg).  
In this test, the protective action against wear of the CMCA composite material is more 
evident than in the test performed in the knee simulator, showing a reduction of wear of 
about the 86% instead of two thirds. The prosthetic type was not the same in the two 
tests (knee or hip prosthesis) but the UHMWPE liners were in reciprocal movement with 
a CoCrMo component (femoral component or prosthetic head). Comparing the wear 
rate for the UHMWPE liners immersed in the viscoelastic fluid the results are very 
similar: 3 mg per million cycles in the knee joint test and 4,92 mg per million cycles in 
this test. This means that the ability to protect from wear remains in both situations. 
Comparing the CoCrMo heads used in this test and the ones used in the other hip joint 
test, with MoM prostheses, it can be observed that the wear on MoM prostheses is 
slightly higher but it has to be considered that these heads were previously tested for 
five million cycles. 
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CHAPTER 5: CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
This thesis work presented the characterization of the manufacturing process for the 
CMCA polymer-gel considering packaging, sterilization, storage and product 
characteristics as non pyrogenicity and stability. In addition, three mechanical tests were 
performed to evaluate product performances in term of lubricating and wear-
protection, which are essential properties for a viscosupplementation device.  
The best package conditions, characterized by glass syringe, filled under nitrogen, and 
contained in a plastic blister, were identified by different tests such as the IR, the pH and 
the rheometric analyses. It was demonstrated that material degradation was reduced 
with nitrogen filling in comparison with the case of the air used as propeller in the 
automatic filling technique. The evidence that the packaging materials did not influence 
chemical and physical characteristics of the product was given by pH and IR analysis. 
The choice of the proper sterilization procedure has to balance two opposite needs: 
guarantee sterility and to not induce an excessive damage in the mechanical 
characteristics of the treated product. To identify the best sterilization cycle, three 
different cycles were designed and tested. The most conservative was chosen after the 
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results coming from the rheological comparison, showing the effects on the Elastic and 
Viscous Moduli, induced by the treatment.  
The non pyrogenicity was determined by test on rabbit, according to the fifth edition of 
the European Pharmacopeia, that allows to find out the pyrogenicity of the material 
itself and/or the pyrogenicity induced by the presence of microorganisms or their parts. 
The test, performed on three rabbits, was successfully passed stating the non 
pyrogenicity of the device. 
Analysing the manufacturing process, it was noted the necessity to perform two 
controls: the first to check if the CMCA polymer concentration is correct to continue 
with the following working phases; the second on the final product, to verify that the 
hydration procedure have been performed correctly to obtain the product with the 
desiderated concentration. Due to the fact that the density is related to concentration, 
the density test was chosen to get information on the correct concentration of the 
tested material and this is why a testing procedure was developed and the relationship 
between concentration and density was investigated.  
Stability and shelf life are important characteristics to be determined while 
characterizing a new medical device because of the necessity to know the period of time 
in which it maintains adequate characteristics and performances. The product was 
studied giving attention to the characteristics susceptible to change in time such as the 
Elastic and the Viscous Moduli. They were monitored with both real time test, in two 
months, and accelerated test, exposing the material to high temperature (40°C or 50°C) 
for eight days. Preliminary accelerated tests shown that the standard parameter, to find 
out the correspondence between high temperature days and room temperature days, 
was not suitable for the CMCA polymer gel. To avoid this problem, a model of the 
possible drop in time of the considered characteristics in worst case condition was 
created, according to which the study was performed. The analysis of the values of both 
moduli, after the considered period of time, was performed with a rheometric study. 
The study allowed finding the characteristic value for the Q10 aging factor of the CMCA 
polymer-gel composite material, for the temperatures considered. The importance of 
this result is due to the fact that now it is possible to perform an accelerated test, at a 
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precise temperature (between 22,5°C and 50°C) and for a specific period of time, to 
simulate real aging and to investigate product’s shelf life.  
Storage conditions could highly influence the product’s aging so a comparison between 
the storage at room temperature and the storage at 4°C was performed. The effect of 
temperature on aging and storage was evaluated by a frequent sweep test performed 
with a rotational rheometer, in order to investigate the G’ and G” values in time at the 
different frequencies, with particular attention to 0,5 Hz and 2,5 Hz corresponding to the 
walking and running conditions. This test shown that is preferable to store the product 
at 4°C than at 22,5°C and allowed to affirm that the CMCA composite material presents 
good resistance of the Elastic and Viscous Moduli in six months storage at 4°C. 
The tests were done to develop manufacturing processes and to operate a control on it, 
while the mechanical tests, which follows, were designed to evaluate the CMCA 
composite performances in situations similar to the intended use. 
The first mechanical test was performed on the knee joint simulator, a machine that 
reproduces the knee motion with the help of a prosthetic knee. The CMCA polymer-gel 
was used as lubricating fluid and was diluted, with BCS, to simulate the worst case and 
the possible dilution that can occur while injected in a knee that has not been treated 
with arthrocentesis. The effects were studied comparing these consequences to the 
ones caused by the lubrication in serum (BCS and deionized water) giving evidence of 
the best lubricating properties of the CMCA composite material in term of wear 
reduction and surfaces protection. These conclusions were obtained by the wear 
evaluation given by weighting measures of the absorption and material loss in the liners 
and by surfaces analysis.  
The second test, performed on the hip joint simulator, was designed to evaluate a new 
possible use for the material as a device to be injected in patients with MoM total hip 
prosthesis. This kind of prostheses are characterised by ion delivery with consequent 
arise of adverse effects. It was compared the ion delivery of four prostheses, which had 
worked before for about five million cycles: two were immersed in CMCA polymer-gel, 
diluted in BCS, and two in serum (BCS and deionized water). The relationship between 
wear and ion delivery was investigated to confirm that the greater the wear is, the 
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greater the numbers of metal ions particles is. Comparing the stations equipped with 
prostheses presenting similar initial wear degree, the test highlighted that the 
lubrication made with a viscoelastic fluid reduces wear and, because of this, reduces the 
ion delivery. This fact assumes great importance considering the adverse effects caused 
by metal particles. They could be reduced by the use of a viscoelastic lubricant medium 
such as the CMCA composite material. Even if the test was performed in a worst case, 
diluting CMCA polymer-gel with BCS, it was clear that it presented better lubricating 
behaviour than BCS and deionized water, used to recreate physiological wear-rates. 
To obtain another confirm that CMCA polymer-gel composite material is a device able to 
reduce wear and prevent surface damages another test was performed. This test was 
conducted again on the hip joint simulator, but using a different type of prostheses. 
They were characterised by the presence of CoCrMo heads, as in the previous test, but 
the liners were made of UHMWPE. At the end of the test, after one million cycles, the 
wear behaviour for liners and heads, immersed in serum or in diluted CMCA mixture, 
was evaluated, confirming that the presence of a viscoelastic fluid greatly reduces wear.  
Comparing the wear of the liners in UHMWPE used in this test and in test performed on 
the knee joint simulator, it was clear that the wear behaviour, in diluted CMCA 
composite was comparable, even in different testing conditions. 
If the comparison between the CoCrMo heads used in this test and the ones used in the 
other hip joint test is done, it can be noticed that the wear in the first case was lower 
but it has to be taken into consideration the fact that, in the second case, the heads 
were previously used for 5 million cycles. 
In conclusion, all the tests performed allowed stating that the product presents 
adequate characteristics to be used as a viscosupplementation device not only 
considering its rheological characterisation, but also its stability over time and its 
mechanical action in wear prevention and surfaces protection.  
The pyrogenicity test concluded that the CMCA polymer-gel composite material is non-
pyrogenic giving evidence of its safety. 
Viscosupplementation is not the only possible use for the product: thanks to the metal 
ions test, it was possible to demonstrate that it could be used in patients with MoM 
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prostheses to reduce the metal ion release preventing the increase of adverse effects 
and giving the possibility to retard revision surgery. 
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